Commonwealth Numbered Regulations

[Index] [Table] [Search] [Search this Regulation] [Notes] [Noteup] [Previous] [Download] [Help]

HEALTH INSURANCE (PATHOLOGY SERVICES TABLE) REGULATIONS 2004 2004 NO. 309 - SCHEDULE 1

Table of pathology services

(regulation 5)

Part 1 Prescription of table

1A Prescription of table
For section 4A of the Act, these Regulations prescribe a table of pathology services that sets out:

(a)
in Part 2 — rules for interpretation of the table; and

(b) in Part 3:

(i)
items of pathology services; and
(ii)
the amount of fees applicable for each item; and
(c)
in Parts 4 and 5 — additional supporting information.

Part 2 Rules of interpretation

1 Interpretation of table
(1) In this table:

"item "means:

(a) an item mentioned, by number, in column 1 of:

(i)
Part 3; or
(ii)
Part 3 of the diagnostic imaging services table; or
(iii)
Part 3 of the general medical services table; and
(b)
in a reference immediately followed by a number — the item so numbered.

"patient episode" means:

(a) a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:

(i)
on the same day; or
(ii)
if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days;
whether the services:

(iii)
are requested by 1 or more practitioners; or
(iv)
are described in a single item or in more than 1 item; or
(v)
are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or
(vi)
are rendered on the same or different days; or
(b)
a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relate to the service.

"recognised pathologist" means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.

"serial examinations" means a series of examinations requested on 1 occasion whether or not:

(a)
the materials are received on different days by the approved pathology practitioner; or

(b)
the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

(2)
In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

(3)
A reference to a Group in the table includes every item in the Group and a reference to a Subgroup in the table includes every item in the Subgroup.

2 Precedence of items
(1) If a service is described:

(a)
in an item in general terms; and

(b)
in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

(2) Subject to subrule (3), if:

(a)
subrule (1) does not apply; and

(b)
a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

(3)
If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

Application of items 74990 and 74991
(4) Despite subrules (1), (2) and (3):

(a)
if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and

(b)
if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in this table that applies to the service.

(5)
For items 74990 and 74991:

"bulk-billed", in relation to a pathology service, means:

(a)
a medicare benefit is payable to a person in respect of the service; and

(b) under an agreement entered into under section 20A of the Act:

(i)
the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and
(ii)
the practitioner accepts the assignment in full payment of his or her fee for the service provided.
"Commonwealth concession card holder" means a person who is a concessional beneficiary within the meaning given by subsection 84 (1) of the National Health Act 1953 .

"unreferred service" means a pathology service that:

(a)
is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and

(b)
has not been referred to the medical practitioner by another medical practitioner or person with referring rights.

(6) For item 74991:

"ASGC" means the document titled Australian Standard Geographical Classification (ASGC) 2002, published by the Australian Bureau of Statistics, as in force on 1 July 2002.

"practice location", in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Commission.

regional, rural or remote area means an area classified as RRMAs 3-7 under the Rural, Remote and Metropolitan Areas Classification.

Rural, Remote and Metropolitan Areas Classification has the meaning given by subrule 3 (1) of Part 2 of Schedule 1 to the general medical services table.

"SLA" means a Statistical Local Area specified in the ASGC.

"SSD" means a Statistical Subdivision specified in the ASGC.

3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

(1)
In subrule (2), service includes assay, estimation and test.

(2) Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

(a)
the services are listed in the same item; and

(b)
that item is not item 74990 or 74991; and

(c)
the patient's need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than 1 day.

4 Services to which rule 3 does not apply
(1) Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66515, 66584 or 66800 if:

(a)
the service is rendered in relation to a single specimen taken on each of not more than 6 occasions in a period of 24 hours; and

(b) the service is rendered to an inpatient of a hospital; and

(c)
in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

(d)
the account for the service is endorsed ` Rule 3 Exemption'.

(2) Rule 3 does not apply to any of the following pathology services:

(a)
estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy;

(b)
quantitative estimation of lithium for a patient undergoing lithium therapy;

(c)
a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

(d)
a service described in item 65070 in relation to

clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient;

(e)
a service described in any of items 66500 to 66515, in relation to methotrexate or leflunomide therapy of a patient;

(f) quantitative estimation of urea, creatinine and electrolytes in relation to:

(i)
cis-platinum or cyclosporin therapy of a patient; or
(ii)
chronic renal failure of a patient being treated
in a dialysis program conducted by a recognised hospital;
(g)
quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;

if:

(h)
under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and

(i)
the tests are performed within 6 months of the request; and

(j)
the account for the service is endorsed ` Rule 3 Exemption'.

5 Item taken to refer only to the first service of a particular kind
(1) For an item in Group P1 (Haematology):

(a)
if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

(b) if:

(i)
tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and
(ii)
specimen material from the patient episode is stored; and
(iii)
in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material;
the later tests and the earlier tests are taken to be part of 1 patient episode.

(2)
Items 65102 and 65108 apply only if a minimum of 6 units are issued for a patient's care in any 1 day.

(3) For items 65099 and 65102:

"compatibility tests by crossmatch" means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

6 Certain items not to apply to a service referred by one pathology practitioner to another
(1) In this rule:

"designated pathology service" means a pathology service in respect of tests relating to a single patient episode that are:

(a)
tests of the kind described in item 66695; or

(b)
tests of the kind described in item 66722; or

(c)
tests of the kind described in item 66800; or

(d)
tests of the kind described in item 66812; or

(e)
tests of the kind described in item 69384.

(2) This rule applies in respect of a designated pathology service where:
(a) an approved pathology practitioner ( practitioner A ) in an approved pathology authority:

(i)
has been requested to render the designated pathology service; and
(ii)
is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and
(iii)
requests an approved pathology practitioner ( practitioner B ) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and
(iv)
renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and
(b)
the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66710, 66734, 66806, 66815 or 69399.

(3) If this rule applies in respect of a designated pathology service:

(a)
item 66695, 66698, 66701, 66704, 66707, 66722, 66725, 66728, 66731, 66800, 66803, 66812, 69384, 69387, 69390, 69393 or 69396 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

(b)
where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (4), the amount specified in item 66713, 66737, 66809, 66818 or 69402 (as the case requires) is payable for each test that the service comprises.

(4) For paragraph (3) (b), the maximum number of tests to which item 66713, 66737, 66809, 66818 or 69402 applies is:
(a) for item 66809:

3 - X; and

(b) for item 66818:
2 - X; and

(c) for item 66713, 66737 or 69402:
6 - X;

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

(5)
Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

7 Items not to be split

Except as stated in rule 6, the amount specified in an item is payable only to 1 approved pathology practitioner in respect of a single patient episode.

8 Creatinine ratios — Group P2 (Chemical)
A pathology service mentioned in an item in Group P2 (Chemical) (except item 66500) that:

(a)
involves the measurement of a substance in urine; and

(b)
requires calculation of a substance/creatinine ratio;

is taken to include the measurement of creatinine necessary for the calculation.

9 Thyroid function testing
(1) For item 66719:

"abnormal level of TSH" means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

(2)
Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable for a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

(3) The written statement from the medical practitioner must indicate:

(a)
that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or

(b)
that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

(c)
that the patient is on drugs that interfere with thyroid hormone metabolism or function.

10 Meaning of serial examinations or cultures
For an item in Group P3 (Microbiology):
(a) serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:

(i)
the materials are received on different days by the approved pathology practitioner; or
(ii)
the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

(b) if:

(i)
tests are carried out in relation to a patient episode; and
(ii)
specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of 1 patient episode.

11 Investigation for hepatitis serology

(1)
The fee applying in a single patient episode that includes any of items 69475, 69478 and 69481 is the fee specified for 1 only of those items.

(2)
Item 69478 applies to a service in relation to which:

(a)
a practitioner requests 2 tests for immune status or viral carriage; or

(b)
the clinical notes indicate that the service is required for:

(i)
pre-operative assessment; or
(ii)
post-exposure to blood or other body fluids assessment; or
(iii)
assessment before blood or tissue donation.
(3)
Item 69481 applies to a service in relation to a patient who displays 1 or more of the characteristics of acute or chronic hepatitis.

12 Tests in Group P4 (Immunology) relating to antibodies

For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

(a)
tests are carried out in relation to a patient episode; and

(b)
specimen material from the patient episode is stored; and

(c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of 1 patient episode.

13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology)
(1) For items in Group P5 (Tissue pathology):

"biopsy material" means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner:

(a)
from a medical procedure, or group of medical procedures, performed on a patient at the same time; or

(b)
after being expelled spontaneously from a patient.

"cytology" means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate.

"separately identified specimen" means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

(2)
For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

(3)
For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

(4)
If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.

(5)
If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, only the fee for the examination having the highest specified fee is applicable to the examinations.

(6)
In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 5 of this table.

(7)
If:

(a)
more than 1 of the services mentioned in items 72846, 72847 and 72848; or

(b)
more than 1 of the services mentioned in items 73059, 73060 and 73061;

are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances
(1) For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

"approved collection centre" has the same meaning as in Part IIA of the Act.

"institution" means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

(a)
disadvantaged children; or

(b)
juvenile offenders; or

(c)
aged persons; or

(d)
chronically ill psychiatric patients; or

(e)
homeless persons; or

(f)
unemployed persons; or

(g)
persons suffering from alcoholism; or

(h)
persons addicted to drugs; or

(i)
physically or mentally handicapped persons;

but does not include:

(j)
a hospital; or

(k)
a residential care facility; or

(l)
accommodation for aged persons that is attached to a residential care facility or situated within a residential care facility complex.

"prescribed laboratory" means a laboratory operated by:

(a)
the Commonwealth; or

(b)
an authority of the Commonwealth; or

(c)
a State or internal Territory; or

(d)
an authority of a State or internal Territory; or

(e)
an Australian tertiary education institution.

"residential care facility" means a facility in which residential care, within the meaning of section 41-3 of the Aged Care Act 1997 , is provided.

"specimen collection centre" has the same meaning as in Part IIA of the Act.

"treating practitioner" has the same meaning as in paragraph 16A (1) (a) of the Act.

(2) If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

(a)
the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

(b)
the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

(c)
the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or

(d)
a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member's employment with the hospital or laboratory.

(3)
An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

(4)
An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service.

(5)
Subject to subrule (7), if 1 item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

(6)
An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

(7) If, in respect of the same patient episode:

(a)
services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or

(b)
services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority;

the fee specified in the applicable item in Group P10 applies to both approved pathology practitioners.

(8) If more than one specimen is collected from a person on the same day for the provision of pathology services:

(a)
in accordance with more than 1 request; and

(b)
in or by a single approved pathology authority;

the fee specified in the applicable item in Group P10 applies once only to the services.

(9)
The fee specified in item 73921 applies only once in respect of a single patient episode.

15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73921 in respect of the patient episode.

16 Circumstances in which an item in Group P11 (Specimen referred) does not apply
(1) An item in Group P11 does not apply to a referral if:

(a)
a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

(b)
the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

(2) An approved pathology authority is related to another approved pathology authority for subrule (1) if:

(a)
both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

(b)
either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c)
both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act 2001 ; or

(d)
the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or

(e)
both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or

(f)
both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.

(3)
An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66515, 66536, 66596, 69300, 69303, 69333 or 73527.

17 Abbreviations

(1)
The abbreviations in Part 4 may be used to identify particular pathology services or groups of pathology services.

(2)
The names of services or drugs not listed in Part 4 must be written in full.

18 Certain pathology services to be treated as 1 service
(1) In this rule:

"general practitioner" means a medical practitioner who:

(a)
is not a consultant physician in any specialty; and

(b)
is not a specialist in any specialty.

"set of pathology services" means a group of pathology services:

(a)
that consists of services that are described in at least 4 different items; and

(b)
all of which are requested in a single patient episode; and

(c)
each of which relates to a patient who is not an admitted patient of a hospital; and

(d) none of which is referred to:

(i)
in item 66713, 66737, 66809, 66818, 69402, 69484, 73053 or 73055; or
(ii)
in an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred) or Group P12 (Management of bulk-billed services).
(2)
If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

(3) If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

(a)
the pathology service described in the first-mentioned item is to be treated as 1 pathology service; and

(b) either:

(i)
the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as 1 pathology service; or
(ii)
if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as 1 pathology service; and
(c)
the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

(4) If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

(a)
the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

(b)
the pathology service in the set that is described in the item that specifies the highest fee, and has the second-lowest item number, is to be treated as 1 pathology service; and

(c)
the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

(5)
If pathology services are to be treated as 1 pathology service under paragraph (3) (c) or (4) (c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1 pathology service.

19 Hepatitis C viral RNA testing
For items 69442, 69444 and 69445:

"Hepatitis C sero-positive", for a patient, means 2 different assays of Hepatitis C antibodies are positive.

"serological status is uncertain", for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

20 Haemochromatosis testing
For item 66794:

"elevated serum ferritin", for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

21 Serum B12 and red cell folate testing

(1)
Items 66599 and 66602 do not apply to more than 3 patient episodes that include a service described in item 66599 or 66602, or any combination of those items, in a 12 month period.

(2)
Item 66599 does not apply to a service described in that item if the service was provided as part of the same patient episode as a service described in item 66602.

22 Nutritional and toxicity metals testing
(1) For this rule:

"metal toxicity testing group" means items 66672 and 66673.

"nutritional metals testing group" means items 66669 and 66670.

(2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:

(a)
that item; or

(b)
the other item in the same group; or

(c)
an item in the other group.

23 Antineutrophil cytoplasmic antibody tests

For subsection 16A (3) of the Act, a request for an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if:

(a)
the immunofluorescence test performed as a result of the request is abnormal; or

(b)
a previous immunofluorescence test was abnormal; or

(c)
those antibodies have been previously detected.

24 Satisfying requirements described in pathology service

Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 3 is satisfied if:

(a)
in the case of a requirement for information, the information:

(i)
is included in the request for the service; or
(ii)
was supplied in writing on an earlier occasion to the approved pathology authority that rendered the service, and has been kept by the approved pathology authority; or
(b)
in the case of a requirement for laboratory test results, the results are:

(i)
included in the request for the service; or
(ii)
obtained from another laboratory test performed in the same patient episode; or
(iii)
included in results from an earlier laboratory test that have been kept by the approved pathology authority.

Part 3 Services and fees

Item


Pathology service


Fee ($)


Group P1 — Haematology


65060


Haemoglobin, erythrocyte sedimentation rate, blood viscosity — 1 or more tests


7.95


65066


Examination of:

(a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or
(b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha-naphthyl acetate esterase or chloroacetate esterase; or
(c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or
(d) a urinary sediment for haemosiderin;
including a service described in item 65072


10.55


65070


Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested) — 1 or more instrument-generated set of results from a single sample and (if performed):
(a) a morphological assessment of a blood film; and
(b) any service in item 65060 or 65072


17.20


65072


Examination for reticulocytes including a reticulocyte count by any method — 1 or more tests in any patient episode


10.30


65075


Haemolysis or metabolic enzymes — assessment by 1 or more of the following tests:

(a) erythrocyte autohaemolysis test;
(b) erythrocyte osmotic fragility test;
(c) sugar water test;
(d) G-6-P D (qualitative or quantitative) test;
(e) pyruvate kinase (qualitative or quantitative) test;
(f) acid haemolysis test;
(g) quantitation of muramidase in serum or urine;
(h) Donath Landsteiner antibody test;
(i) other erythrocyte metabolic enzyme tests


52.90


65078


Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of:

(a) examination for HbH; or
(b) quantitation of HbA2; or
(c) quantitation of HbF;

including (if performed) any service described in item 65060 or 65070


91.75


65081


Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of:

(a) heat denaturation test; or
(b) isopropanol precipitation test; or
(c) tests for the presence of haemoglobin S; or
(d) quantitation of any haemoglobin fraction (including S, C, D, E);

including (if performed) any service described in item 65060, 65070 or 65078


98.25


65084


Bone marrow trephine biopsy — histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):

(a) special stains or immunohistochemical techniques (if any); and
(b) any test described in item 65060, 65066 or 65070


168.75


65087


Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed):

(a) special stains or immunohistochemical techniques (if any); and
(b) any test described in item 65060, 65066 or 65070


84.55


65090


Blood grouping (including back-grouping if performed) — ABO and Rh (D antigen)


11.25


65093


Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including item 65090 (if performed)


22.35


65096


Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:

(a) identification and quantitation of any antibodies detected; and
(b) (if performed) any test described in item 65060 or 65070


41.65


65099


Compatibility tests by crossmatch — all tests performed on any one day for up to 6 units, including:

(a) all grouping checks of the patient and donor; and
(b) examination for antibodies, and if necessary identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096

(Item is subject to rule 5)


113.40


65102


Compatibility tests by crossmatch — all tests performed on any one day in excess of 6 units, including:

(a) all grouping checks of the patient and donor; and
(b) examination for antibodies, and if necessary identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105

(Item is subject to rule 5)


170.10


65105


Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day for up to 6 units, including:

(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096

(Item is subject to rule 5)


113.40


65108


Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day in excess of 6 units, including:

(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105

(Item is subject to rule 5)


170.10


65111


Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)


23.60


65114


1 or more of the following tests:

(a) direct Coombs (antiglobulin) test;
(b) qualitative or quantitative test for cold agglutinins or heterophil antibodies


9.25


65117


1 or more of the following tests:

(a) spectroscopic examination of blood for chemically altered haemoglobins;
(b) detection of methaemalbumin (Schumm's test)


20.60


65120


Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D-dimer — 1 test


14.05


65123


2 tests described in item 65120


20.60


65126


3 tests described in item 65120


28.35


65129


4 or more tests described in item 65120


36.10


65132


Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism — quantitation by 1 or more techniques — 1 test


25.75


65133


2 tests described in item 65132


49.50


65134


3 tests described in item 65132


73.20


65135


4 tests described in item 65132


96.90


65136


5 tests described in item 65132


120.65


65137


Test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65132, 65133, 65134, 65135 or 65136 applies


25.75


65142


Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65132, by testing a specimen collected on a different day — 1 or more tests


25.75


65144


Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs — 1 or more tests


57.55


65147


Quantitation of anti-Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid — 1 test


38.55


65150


Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay — 1 test


72.15


65153


2 tests described in item 65150


144.35


65156


3 or more tests described in item 65150


216.50


65159


Quantitation of circulating coagulation factor inhibitors by Bethesda assay — 1 test


72.15


65162


Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)


10.55


65165


Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162


35.05


65168


Characterisation of the genotype of a patient for factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism — 1 or more tests


37.10


65171


Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item — 1 or more tests


25.75


65174


Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item 65168 — 1 or more tests


37.10


65200


Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of:

(a) acute myeloid leukaemia; or
(b) acute promyelocytic leukaemia; or
(c) acute lymphoid leukaemia; or
(d) chronic myeloid leukaemia;

each test to a maximum of 4 tests in a 12 month period


235.00


Group P2 — Chemical


66500


Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total cholesterol, total protein, triglycerides, urate or urea — 1 test


9.75


66503


2 tests described in item 66500


11.75


66506


3 tests described in item 66500


13.75


66509


4 tests described in item 66500


15.75


66512


5 tests described in item 66500


17.80


66515


6 or more tests described in item 66500


19.80


66518


Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in plasma or serum — tests on only 1 specimen, in a 24 hour period


20.40


66519


Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in plasma or serum — tests on 2 or more specimens, in a 24 hour period


40.85


66536


Quantitation of HDL cholesterol


11.25


66539


Electrophoresis of serum for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaemia — each patient episode to a maximum of 2 patient episodes in a 12 month period


31.15


66542


Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes:

(a) administration of glucose; and
(b) at least 2 measurements of blood glucose; and
(c) (if performed) any test described in item 66695


19.30


66545


Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:

(a) administration of glucose; and
(b) 1 or 2 measurements of blood glucose; and
(c) (if performed) any test in item 66695


16.10


66548


Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:

(a) administration of glucose; and
(b) at least 3 measurements of blood glucose; and
(c) (if performed) any test in item 66695


20.30


66551


Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period


17.10


66554


Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant — each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)


17.10


66557


Quantitation of fructosamine performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period


9.85


66560


Microalbumin — quantitation in urine 


20.50


66563


Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests


25.10


66566


Quantitation of:

(a) blood gases (including pO 2 , oxygen saturation and pCO 2 ); and
(b) bicarbonate and pH;

including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen — 1 or more tests on 1 specimen


34.30


66569


Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day


43.35


66572


Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day


52.45


66575


Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day


61.50


66578


Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day


70.55


66581


Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day


79.65


66584


Quantitation of ionised calcium (except if performed as part of item 66566) — 1 test


9.85


66587


Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen


48.35


66590


Calculus, analysis of 1 or more


31.15


66593


Ferritin — quantitation, except if requested as part of iron studies


18.35


66596


Iron studies, consisting of quantitation of:

(a) serum iron; and
(b) transferrin or iron binding capacity; and
(c) ferritin


33.10


66599


Serum B12 or red cell folate and, if required, serum folate
(Item is subject to rule 21)


24.05


66602


Serum B12 and red cell folate and, if required, serum folate
(Item is subject to rule 21)


43.75


66605


Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid — 1 or more tests within a 6 month period


31.15


66608


Vitamin D or D fractions — 1 or more tests


43.00


66623


All qualitative and quantitative tests on blood, urine or other body fluid for:

(a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or
(b) ingested or absorbed toxic chemicals;

including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding:

(c) the surveillance of sports people and athletes for performance improving substances; and
(d) the monitoring of patients participating in a drug abuse treatment program


42.25


66626


Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program; but excluding the surveillance of sports people and athletes for performance improving substances; including all tests on blood, urine or other body fluid — each patient episode, to a maximum of 36 episodes in a 12 month period


24.55


66629


Beta-2-microglobulin — quantitation in serum, urine or other body fluids — 1 or more tests


20.50


66632


Caeruloplasmin, haptoglobins, or prealbumin — quantitation in serum, urine or other body fluids — 1 or more tests


20.50


66635


Alpha-1-antitrypsin — quantitation in serum, urine or other body fluid — 1 or more tests


20.50


66638


Isoelectric focussing or similar methods for determination of alpha-1-antitrypsin phenotype in serum — 1 or more tests


29.70


66641


Electrophoresis of serum or other body fluid to demonstrate:

(a) the isoenzymes of lactate dehydrogenase; or
(b) the isoenzymes of alkaline phosphatase;

including the preliminary quantitation of total relevant enzyme activity — 1 or more tests


29.70


66644


C-1 esterase inhibitor — quantitation


20.50


66647


C-1 esterase inhibitor — functional assay


45.90


66650


Alpha-fetoprotein, CA-15.3 antigen (CA15.3), CA-19.9 antigen (CA19.9), CA-125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour — quantitation — 1 test


24.75


66653


2 or more tests described in item 66650


45.35


66655


Prostate specific antigen (PSA) quantitation — 1 patient episode in a 12 month period


20.50


66656


Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item 66655 applies)


20.50


66659


Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index in the follow up of a PSA result that lies in the equivocal range of the particular method of assay used to determine the level — 1 test (including a test to which item 66656 applies) in a 12 month period


37.80


66662


Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests


81.35


66665


Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test


31.15


66667


Quantitation of serum zinc in a patient receiving intravenous alimentation — each test


31.15


66669


Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 1 test, to a maximum of 3 patient episodes, in a 6 month period
(Item is subject to rule 22)


31.15


66670


Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 2 or more tests, to a maximum of 3 patient episodes, in a 6 month period
(Item is subject to rule 22)


53.35


66671


Quantitation of serum aluminium in a patient in a renal dialysis program — each test


37.55


66672


Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue — 1 test, to a maximum of 3 patient episodes, in a 6 month period 
(Item is subject to rule 22)


31.15


66673


Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue — 2 or more tests, to a maximum of 3 patient episodes, in a 6 month period
(Item is subject to rule 22)


53.35


66674


Quantitation of:

(a) faecal fat; or
(b) breath hydrogen in response to loading with disaccharides;

1 or more tests within a 28 day period


40.65


66677


Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old


11.35


66680


Quantitation of disaccharidases and other enzymes in intestinal tissue — 1 or more tests


75.75


66683


Enzymes — quantitation in solid tissue or tissues other than blood elements or intestinal tissue — 1 or more tests


75.75


66686


Performance of 1 or more of the following procedures:

(a) growth hormone suppression by glucose loading;
(b) growth hormone stimulation by exercise;
(c) dexamethasone suppression test;
(d) sweat collection by iontophoresis for chloride analysis;
(e) pharmacological stimulation of growth hormone


51.55


66689


Personal performance by a recognised pathologist of 1 of the following procedures:

(a) gonadotrophin releasing hormone stimulation test;
(b) synacthen stimulation test;
(c) glucagon stimulation test with C-peptide measurement;
(d) pentagastrin or calcium stimulation of thyrocalcitonin release;
(e) secretin or calcium stimulation of gastrin release;
(f) insulin hypoglycaemia;
(g) arginine infusion;
(h) thyrotrophin releasing hormone (TRH) test


82.50


66692


Personal performance by a recognised pathologist of 2 or more tests described in item 66689


144.35


66695


Quantitation in blood or urine of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF -1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test


30.70


66698


2 tests described in item 66695
(Item is subject to rule 6)


43.80


66701


3 tests described in item 66695
(Item is subject to rule 6)


57.20


66704


4 tests described in item 66695
(Item is subject to rule 6)


70.60


66707


5 tests described in item 66695
(Item is subject to rule 6)


84.05


66710


6 or more tests described in item 66695
(Item is subject to rule 6)


97.45


66713


Tests described in item 66695, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests
(Item is subject to rule 6)


13.40


66716


TSH quantitation


25.45


66719


Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied:

(a) the patient has an abnormal level of TSH;


35.45



(b) the tests are performed:
(i) for the purpose of monitoring thyroid disease in the patient; or
(ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or
(iii) to investigate dementia or psychiatric illness of the patient; or
(iv) to investigate amenorrhoea or infertility of the patient;
(c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;
(d) the patient is on drugs that interfere with thyroid hormone metabolism or function

(Item is subject to rule 9)



66722


TSH quantitation described in item 66716 and 1 test described in item 66695
(Item is subject to rule 6)


38.55


66725


TSH quantitation described in item 66716 and 2 tests described in item 66695
(Item is subject to rule 6)


51.95


66728


TSH quantitation described in item 66716 and 3 tests described in item 66695
(Item is subject to rule 6)


65.35


66731


TSH quantitation described in item 66716 and 4 tests described in item 66695
(Item is subject to rule 6)


78.75


66734


TSH quantitation described in item 66716 and 5 tests described in item 66695
(Item is subject to rule 6)


92.15


66737


Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests
(Item is subject to rule 6)


13.40


66743


Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751


20.50


66749


Amniotic fluid, spectrophotometric examination of, and quantitation of:

(a) lecithin/sphingomyelin ratio; or
(b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or
(c) bilirubin, including correction for haemoglobin;

1 or more tests


33.50


66750


Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality:

(a) total human chorionic gonadotrophin (total HCG);
(b) free alpha human chorionic gonadotrophin (free alpha HCG);
(c) free beta human chorionic gonadotrophin (free beta HCG);
(d) pregnancy associated plasma protein A (PAPP-A);


40.45



(e) unconjugated oestriol (uE 3 );
(f) alpha-fetoprotein (AFP);

including (if performed) a service described in item 73527 or 73529 — 1 patient episode in a pregnancy



66751


Quantitation, in pregnancy, of any 3 or more tests described in item 66750


56.20


66752


Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776) — 1 test


25.10


66755


2 or more tests described in item 66752


39.50


66758


Quantitation of angiotensin converting enzyme, or cholinesterase — 1 or more tests


25.10


66761


Test for reducing substances in faeces by any method (except reagent strip or dipstick)


13.40


66764


Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:

(a) an immunological method; and
(b) a chemical method (except reagent strip or dip stick);

with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods


9.05


66767


2 examinations by both methods described in item 66764 performed on separately collected and identified specimens


18.15


66770


3 examinations by both methods described in item 66764 performed on separately collected and identified specimens


27.20


66773


Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66752 — 1 or more tests


25.10


66776


Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget's disease of bone, and if performed, a service described in item 66752 — 1 or more tests


25.10


66779


Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin — quantitation — 1 or more tests


40.65


66782


Porphyrins or porphyrins precursors — detection in plasma, red cells, urine or faeces — 1 or more tests


13.40


66785


Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 1 test


40.65


66788


Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 2 or more tests


67.00


66791


Porphyrin biosynthetic enzymes — measurement of activity in blood cells or other tissues — 1 or more tests


75.75


66794


Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:

(a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or
(b) the patient has a first degree relative with haemochromatosis; or
(c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis

(Item is subject to rule 20)


37.10


66800


Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin — 1 test
(Item is subject to rule 6)


18.45


66803


2 tests described in item 66800
(Item is subject to rule 6)


31.05


66806


3 tests described in item 66800
(Item is subject to rule 6)


43.60


66809


Tests described in item 66800, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 2 tests


12.60


66812


Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test
(Item is subject to rule 6)


35.45


66815


2 tests described in item 66812
(Item is subject to rule 6)


60.60


66818


Tests described in item 66812, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 1 test
(Item is subject to rule 6)


25.15


Group P3 — Microbiology


69300


Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:

(a) differential cell count (if performed); or
(b) examination for dermatophytes; or
(c) dark ground illumination; or
(d) stained preparation or preparations using any relevant stain or stains;

1 or more tests


12.60


69303


Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses) from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; or
(b) the detection of antigens not elsewhere described in this table; or
(c) a service described in item 69300;

specimens from 1 or more sites


22.15


69306


Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from skin or other superficial sites, including (if performed):

(a) the detection of antigens not elsewhere specified in this table; or
(b) pathogen identification and antibiotic susceptibility testing; or
(c) a service described in items 69300, 69303, 69312, 69318 and 73810;

1 or more tests on 1 or more specimens


34.00


69309


Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):

(a) the detection of antigens not elsewhere specified in this table; or
(b) a service described in items 69300, 69303, 69306, 69312, 69318 and 73810;

1 or more tests on 1 or more specimens


48.45


69312


Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):

(a) the detection of antigens not elsewhere specified in this table; or
(b) pathogen identification and antibiotic susceptibility testing; or
(c) a service described in items 69300, 69303, 69306 and 69318;

1 or more tests on 1 or more specimens


34.00


69315


Microscopy and culture to detect pathogenic micro-organisms and the detection of chlamydia from urethra, vagina, cervix or rectum and including (if performed):

(a) the detection of microbial antigens; or
(b) pathogen identification and antibiotic susceptibility testing; or
(c) a service described in item 69300, 69303, 69306, 69312, 69318, 69363, 69369, 69370, 69372, 69375 or 73810;

1 or more tests on 1 or more specimens


62.70


69318


Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):

(a) the detection of antigens (from any type of specimen) not elsewhere specified in this table, including item 69372; or
(b) pathogen identification and antibiotic susceptibility testing; or


34.00



(c) a service described in items 69300, 69303, 69306 and 69312;

1 or more tests on 1 or more specimens



69321


Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; or
(b) the detection of antigens not elsewhere specified in this table; or
(c) a service described in item 69300, 69303, 69306, 69312 or 69318;

specimens from 1 or more sites


48.45


69324


Microscopy (with appropriate stains) and culture for mycobacteria — 1 specimen of sputum, urine or other body fluid or 1 operative or biopsy specimen, including (if performed):

(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;

including a service mentioned in item 69300


43.30


69327


Microscopy (with appropriate stains) and culture for mycobacteria — 2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):

(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;

including a service described in item 69300


85.55


69330


Microscopy (with appropriate stains) and culture for mycobacteria — 3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):

(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;

including a service described in item 69300


128.85


69333


Urine examination (including serial examination) by any means other than simple culture by dip slide, including:

(a) cell count; and
(b) culture; and
(c) colony count; and
(d) (if performed) identification of cultured pathogens; and
(e) (if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts


20.70


69336


Microscopy of faeces for ova, cysts and parasites using concentration techniques including the use of fixed stains or antigen detection for cryptosporidia and giardia, including (if performed) a service mentioned in item 69300 — not more than 1 examination in a 7 day period


33.65


69339


Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336 — not more than 1 examination in a 7 day period


19.25


69345


Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; and
(b) the detection of clostridial toxins; and
(c) a service described in item 69300

Not more than 1 examination in a 7 day period


53.25


69354


Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):

(a) identification of any cultured pathogen; and
(b) necessary antibiotic susceptibility testing;

to a maximum of 3 sets of cultures — 1 set of cultures


30.95


69357


2 sets of cultures described in item 69354


61.85


69360


3 sets of cultures described in item 69354


92.80


69363


Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345, 69369, 69370, 69372, 69373 or 69375 has been performed) — 1 or more tests


28.85


69369


Detection of chlamydia by any method in specimens from 1 or more sites


28.85


69370


Detection of chlamydia by any method and Neisseria gonorrhoeae by nucleic acid amplification techniques in specimens from 1 or more sites


36.10


69372


Detection of microbial antigens or nucleic acids (not elsewhere described in this table) — 1 or more tests


28.85


69373


Detection of a virus or microbial antigen or nucleic acid from a respiratory tract specimen — 1 test


28.85


69374


2 or more tests described in item 69373


36.10


69375


Examination for Herpes simplex virus, varicella zoster virus or cytomegalovirus by culture or by detection of microbial antigen or nucleic acid, including a service described in item 69363, 69369, 69370, 69372 or 69373 (if performed) — 1 test


28.85


69376


2 or more tests described in item 69375


36.10


69378


Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy — 1 or more assays on 1 or more specimens in any 1 patient episode


181.45


69381


Quantitation of HIV viral RNA load in plasma or serum in the monitoring of antiretroviral therapy in a HIV sero-positive patient — 1 or more assays on 1 or more specimens in any 1 patient episode


181.45


69382


Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero-positive patient — 1 or more assays on 1 or more specimens in any 1 patient episode


181.45


69384


Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in this table — 1 test
(Item is subject to rule 6)


15.75


69387


2 tests described in item 69384
(Item is subject to rule 6)


28.85


69390


3 tests described in item 69384
(Item is subject to rule 6)


43.30


69393


4 tests described in item 69384
(Item is subject to rule 6)


57.75


69396


5 tests described in item 69384
(Item is subject to rule 6)


72.15


69399


6 or more tests described in item 69384


86.60


69402


Tests described in item 69384, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests
(Item is subject to rule 6)


14.45


69405


Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:

(a) the determination of 1 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and
(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481


15.75


69408


Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:

(a) the determination of 2 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and
(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481


28.00


69411


Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:

(a) the determination of 3 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and
(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481


39.35


69413


Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:

(a) the determination of all of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and
(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481


50.65


69442


Quantitation of HCV RNA load in plasma or serum in the pre-treatment evaluation or the assessment of efficacy of antiviral therapy of a patient with chronic HCV hepatitis — where the test is requested by or on the advice of the specialist or consultant physician who manages the treatment of the patient with chronic HCV hepatitis (including a service in item 69444 or 69445) — not more than 2 tests in a 12 month period


181.45


69443


Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if:

(a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and
(b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient
Not more than 1 episode in a 12 month period


206.20


69444


Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:

(a) the patient is Hepatitis C seropositive;
(b) the patient's serological status is uncertain after testing;
(c) the test is performed for the purpose of:
(i) determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or


92.80



(ii) the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient

Not more than 1 patient episode in a 12 month period
(Item is subject to rule 19)



69445


Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69444) — not more than 4 patient episodes in a 12 month period
(Item is subject to rule 19)


92.80


69471


Test of cell-mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient — 1 test


35.15


69472


Detection of antibodies to Epstein Barr Virus using specific serology — 1 test


15.75


69474


Detection of antibodies to Epstein Barr Virus using specific serology — 2 or more tests


28.85


69475


Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 1 test, including:

(a) Hepatitis A antibody test; or
(b) Hepatitis B antibody or antigen test; or
(c) Hepatitis C antibody test; or
(d) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive
(Item is subject to rule 11)


15.75


69478


Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 2 tests, including:

(a) Hepatitis A antibody test; or
(b) Hepatitis B surface or core antibody test; or
(c) Hepatitis B surface antigen test; or
(d) Hepatitis B `e' antibody or `e' antigen test; or
(e) Hepatitis C antibody test; or
(f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive
(Item is subject to rule 11)


29.45


69481


Investigation of infectious causes of acute or chronic hepatitis — 3 tests, including:

(a) Hepatitis A antibody test; or
(b) Hepatitis B core antibody test; or
(c) Hepatitis B `e' antibody or `e' antigen test; or
(d) Hepatitis B surface antibody or surface antigen test; or
(e) Hepatitis C antibody test; or
(f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive
(Item is subject to rule 11)


40.80


69484


Supplementary test for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing


17.20


Group P4 — Immunology


71057


Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:

(a) protein classes; or
(b) presence and amount of paraprotein;

including the preliminary quantitation of total protein, albumin and globulin — 1 specimen type


36.30


71058


Examination as described in item 71057 of 2 or more specimen types


51.40


71059


Electrophoresis and immunofixation, immunoelectrophoresis or isoelectric focussing of:

(a) urine for detection of Bence Jones proteins; or
(b) serum, plasma or other body fluid;

and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised — examination of 1 specimen type (eg serum, urine or CSF)


29.70


71060


Examination as described in item 71059 of 2 or more specimen types


44.80


71062


Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient's serum for comparison purposes — 1 or more tests


44.80


71064


Detection and quantitation of cryoglobulins or cryofibrinogen — 1 or more tests


21.10


71066


Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid — 1 test


14.80


71068


Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid — 1 test


14.80


71069


2 tests described in item 71066, 71068, 71072 or 71074


23.15


71071


3 or more tests described in item 71066, 71068, 71072 or 71074


31.50


71072


Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid — 1 test


14.80


71073


Quantitation of all 4 immunoglobulin G subclasses — each patient episode


108.00


71074


Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid — 1 test


14.80


71075


Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in any 12 month period — each patient episode


23.40


71077


Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12 month period — each patient episode


27.55


71079


Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period — each patient episode


27.30


71081


Quantitation of total haemolytic complement


41.25


71083


Quantitation of complement components C3 and C4 or properdin factor B — 1 test


20.50


71085


2 tests described in item 71083


29.45


71087


3 or more tests described in item 71083


38.35


71089


Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table — 1 test


29.65


71091


2 tests described in item 71089


53.70


71093


3 or more tests described in item 71089


77.80


71095


Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years


41.25


71097


Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required


24.85


71099


Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method


27.00


71101


Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids


17.70


71103


Characterisation of an antibody detected in a service described in item 71101 (including that service)


52.95


71106


Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required


11.50


71109


Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody


35.15


71113


Detection of 2 antibodies described in item 71109


48.25


71115


Detection of 3 antibodies described in item 71109


61.35


71117


Detection of 4 or more antibodies described in item 71109


74.45


71119


Antibodies to tissue antigens not elsewhere specified in this table — detection, including quantitation if required, of 1 antibody


17.65


71121


Detection of 2 antibodies specified in item 71119


21.15


71123


Detection of 3 antibodies specified in item 71119


24.65


71125


Detection of 4 or more antibodies specified in item 71119


28.15


71127


Functional tests for lymphocytes — quantitation other than by microscopy of:

(a) proliferation induced by 1 or more mitogens; or
(b) proliferation induced by 1 or more antigens; or


179.45



(c) estimation of 1 or more mixed lymphocyte reactions;

including a test described in item 65066 or 65070 (if performed), up to a maximum of 2 patient episodes in a 12 month period — each patient episode



71129


2 tests described in item 71127


221.65


71131


3 or more tests described in item 71127


263.90


71133


Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test


10.55


71134


Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)


105.85


71135


Quantitation of neutrophil function, comprising at least 2 of the following:

(a) chemotaxis;
(b) phagocytosis;
(c) oxidative metabolism;
(d) bactericidal activity;

including any test described in item 65066, 65070, 71133 or 71134 (if performed), up to a maximum of 2 patient episodes in a 12 month period — each patient episode


211.60


71137


Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, up to a maximum of 2 patient episodes in a 12 month period — each patient episode


30.80


71139


Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid


105.85


71141


Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens


200.85


71143


Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue


264.55


71145


Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid


431.95


71146


Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count


105.85


71147


HLA-B27 typing


41.25


71149


Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147


110.15


71151


Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens


120.95


71153


Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests:

(a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test;
(b) antineutrophil proteinase 3 antibody (PR3 ANCA) test;
(c) antimyeloperoxidase antibody (MPO ANCA) test;
(d) antiglomerular basement membrane antibody (GBM ANCA) test

(Item is subject to rule 23)


35.15


71155


Testing for the presence of 2 antibodies by tests mentioned in item 71153
(Item is subject to rule 23)


48.25


71157


Testing for the presence of 3 antibodies by tests mentioned in item 71153
(Item is subject to rule 23)


61.35


71159


Testing for the presence of 4 antibodies by tests mentioned in item 71153
(Item is subject to rule 23)


74.45


71163


Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed):

(a) antibodies to gliadin;
(b) antibodies to endomysium;
(c) antibodies to tissue transglutaminase
1 test


25.15


71164


2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed)


40.60


Group P5 — Tissue pathology


72813


Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens
(Item is subject to rule 13)


72.15


72816


Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen
(Item is subject to rule 13)


87.10


72817


Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens
(Item is subject to rule 13)


97.45


72818


Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 or more separately identified specimens
(Item is subject to rule 13)


107.75


72823


Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen
(Item is subject to rule 13)


97.95


72824


Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens
(Item is subject to rule 13)


142.30


72825


Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 to 7 separately identified specimens
(Item is subject to rule 13)


181.45


72826


Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 8 or more separately identified specimens
(Item is subject to rule 13)


195.90


72830


Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens
(Item is subject to rule 13)


190.75


72836


Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens
(Item is subject to rule 13)


293.85


72844


Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system — 1 or more tests


30.95


72846


Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 72848
(Item is subject to rule 13)


43.30


72847


Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies
(Item is subject to rule 13)


57.75


72848


Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies:

(a) oestrogen;
(b) progesterone;
(c) c-erb-B2 (HER2)

(Item is subject to rule 13)


51.55


72851


Electron microscopic examination of biopsy material — 1 separately identified specimen
(Item is subject to rule 13)


185.60


72852


Electron microscopic examination of biopsy material — 2 or more separately identified specimens
(Item is subject to rule 13)


247.45


72855


Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 1 separately identified specimen
(Item is subject to rule 13)


185.60


72856


Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 2 to 4 separately identified specimens
(Item is subject to rule 13)


247.45


72857


Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 5 or more separately identified specimens
(Item is subject to rule 13)


288.70


Group P6 — Cytology


73043


Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests


23.00


73045


Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), 1 or more tests on:

(a) specimens resulting from washings or brushings from sites not specified in item 73043; or
(b) a single specimen of sputum or urine; or
(c) 1 or more specimens of other body fluids


48.95


73047


Cytology of a series of 3 sputum or urine specimens for malignant cells


95.35


73049


Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues


69.60


73051


Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if:

(a) the aspiration is performed by a recognised pathologist; or
(b) a recognised pathologist attends the aspiration and performs a cytological examination during the attendance


171.50


73053


Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each examination:

(a) for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or
(b) if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph (a); or
(c) if there is inadequate information provided to use item 73055


19.60


73055


Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test:

(a) for the management of previously detected abnormalities including precancerous or cancerous conditions; or
(b) for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia


19.60


73057


Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test


19.60


73059


Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 73061
(Item is subject to rule 13)


43.30


73060


Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies
(Item is subject to rule 13)


57.75


73061


Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies:


(a) oestrogen;

(b) progesterone;


(c) c-erb-B2 (HER2)

(Item is subject to rule 13)


51.55


Group P7 — Genetics


73287


Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of 1 or more of any tissue or fluid except blood — 1 or more tests


401.45


73289


Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of blood — 1 or more tests


365.20


73300


Detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where:

(a) the patient exhibits 1 or more of the clinical features of fragile X (A) syndrome, including intellectual disabilities; or
(b) the patient has a relative with a fragile X (A) mutation

1 or more tests


103.10


73305


Detection of genetic mutation of the FMR1 gene by Southern Blot, if the results of a service performed in item 73300 are inconclusive


206.20


Group P8 — Infertility and pregnancy tests


73521


Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner's test)


9.80


73523


Semen examination (other than post-vasectomy semen examination), including:

(a) measurement of volume, sperm count and motility; and
(b) examination of stained preparations; and
(c) morphology; and
(d) (if performed) differential count and 1 or more chemical tests;

no more than 4 patient episodes in a 12 month period — each patient episode


42.50


73525


Sperm antibodies — sperm-penetrating ability — 1 or more tests


28.85


73527


Human chorionic gonadotrophin (HCG) — detection in serum or urine by 1 or more methods for diagnosis of pregnancy — 1 or more tests


10.20


73529


Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527 — 1 test


29.15


Group P9 — Simple basic pathology tests


73801


Semen examination for presence of spermatozoa


6.95


73802


Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test


4.60


73803


2 tests described in item 73802


6.40


73804


3 or more tests described in item 73802


8.20


73805


Microscopy of urine, whether stained or not, or catalase test


4.60


73806


Pregnancy test by 1 or more immunochemical methods


10.20


73807


Microscopy for wet film other than urine, including any relevant stain


6.95


73808


Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807


8.70


73809


Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method


2.35


73810


Microscopy for fungi in skin, hair or nails — 1 or more sites


6.95


73811


Mantoux test


11.30


Group P10 — Patient episode initiation


73901


Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory


8.25


73903


Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital


14.75


73905


Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital


8.25


73907


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected:

(a) until 30 November 2001 — in a licensed collection centre (within the meaning of Part IIA of the Act); or
(b) after that date — in an approved collection centre


17.40


73909


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital


17.70


73910


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing


10.30


73912


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential care facility or institution


17.70


73913


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905, 73907 or items in Group P9) if the specimen is collected from the person by the person


9.80


73915


Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner


9.80


Group P11 — Specimen referred


73921


Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority
(Item is subject to rules 14, 15 and 16)


10.30


Group P12 — Management of bulk-billed services


74990


A pathology service to which an item in this table (other than this item or item 74991) applies if:

(a) the service is an unreferred service; and
(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and
(c) the person is not an admitted patient of a hospital or day-hospital facility; and
(d) the service is bulk-billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service


5.85


74991


A pathology service to which an item in this table (other than this item or item 74990) applies if:

(a) the service is an unreferred service; and
(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and
(c) the person is not an admitted patient of a hospital or day-hospital facility; and


8.80



(d) the service is bulk-billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service; and




(e) the service is provided at, or from, a practice location in:
(i) a regional, rural or remote area; or
(ii) Tasmania; or
(iii) a geographical area included in any of the following SSD spatial units:

(A) Beaudesert Shire Part A
(B) Belconnen
(C) Darwin City
(D) Eastern Outer Melbourne
(E) East Metropolitan
(F) Frankston City




(G) Gosford-Wyong
(H) Greater Geelong City Part A
(I) Gungahlin-Hall
(J) Ipswich City (Part in BSD)
(K) Litchfield Shire
(L) Melton-Wyndham
(M) Mornington Peninsula Shire
(N) Newcastle
(O) North Canberra
(P) Palmerston-East Arm
(Q) Pine Rivers Shire
(R) Queanbeyan




(S) South Canberra
(T) South Eastern Outer Melbourne
(U) Southern Adelaide
(V) South West Metropolitan
(W) Thuringowa City Part A
(X) Townsville City Part A
(Y) Tuggeranong
(Z) Weston Creek-Stromlo
(ZA) Woden Valley
(ZB) Yarra Ranges Shire Part A; or

(iv) the geographical area included in the SLA spatial unit of Palm Island (AC)



Part 4 Abbreviations

Note
A drug that is not mentioned in this Part must be written in full.

Test


Abbreviation


Item


Abnormal haemoglobins


AH


65117


Acetoacetate


ACAT


66500


Acetylcholine receptor — tissue antigens — antibodies


ARA


71109


Acid phosphatase


ACP


66500


Actinomycetes — microbial antibody testing


ACT


69384


Activated Protein C resistance


APC


65132-36, 65142, 65171


Adenovirus — microbial antibody testing


ADE


69384


Adrenal cortex — tissue antigens — antibodies


ADR


71109


Adrenocorticotrophic hormone (ACTH)


ACTH


66695


AFB microscopy and culture of sputum — 1 specimen


AFB1


69324


AFB microscopy and culture of sputum — 2 specimens


AFB2


69327


AFB microscopy and culture of sputum — 3 specimens


AFB3


69330


Alanine aminotransferase


ALT


66500


Albumin


ALB


66500


Alcohol (ethanol)


ETOH


66626, 66800


Aldosterone


ALDS


66695


Alkaline phosphatase


ALP


66500


Alkaline phosphatase — isoenzymes


ALPI


66641


Alpha-1-antitrypsin


AAT


66635


Alpha-fetoprotein


AFP


66650-53, 66743, 66750, 66751


Aluminium


AL


66672-73


Aluminium — renal dialysis


ALR


66671


Amikacin



66800


Amino acids


AA


66752


Amiodarone


AMIO


66812


Amitriptyline


AMIT


66812


Ammonia


NH3


66500


Amniotic fluid examination


AFE


66749


Amylase


AMS


66500


Amylobarbitone


AMYL


66812


Androstenedione


ANDR


66695


Angiotensin converting enzyme


ACE


66758


Antibiotic and antimicrobial chemotherapeutic agents — quantitation


QAA


66800, 66812


Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA


ENAP


71103


Antibodies to extractable nuclear antigens — detection


ENA


71101


Antibodies to nuclear antigens — detection


ANA


71097


Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA


ANAP


71099


Antibodies to tissue antigens — acetylcholine receptor


ARA


71109


Antibodies to tissue antigens — adrenal cortex


ADR


71109


Antibodies to tissue antigens — ANCA- myeloperoxidase


MPO


71153


Antibodies to tissue antigens — ANCA-PR3


PR3


71153


Antibodies to tissue antigens — anti-actin


AACT


71119


Antibodies to tissue antigens — anti-endomysial


EMA


71163


Antibodies to tissue antigens — cardiolipin


ACL


71109


Antibodies to tissue antigens — coeliac disease panel


CLC


71163-64


Antibodies to tissue antigens — gastric parietal cell


PCA


71119


Antibodies to tissue antigens — gliadin IgA


GLIA


71163


Antibodies to tissue antigens — gliadin IgG


GLIG


71163


Antibodies to tissue antigens — glomerular basement membrane


GBM


71153


Antibodies to tissue antigens — heart


AHE


71109


Antibodies to tissue antigens — histone


AHI


71109


Antibodies to tissue antigens — insulin receptor antibodies


INSA


71109


Antibodies to tissue antigens — intercellular cement substance of skin


ICCS


71109


Antibodies to tissue antigens — intrinsic factor


AIF


71109


Antibodies to tissue antigens — islet cell


AIC


71109


Antibodies to tissue antigens — Jo-1


JO1


71119


Antibodies to tissue antigens — keratin


KERA


71119


Antibodies to tissue antigens — liver/kidney microsomes


LKA


71119


Antibodies to tissue antigens — lymphocyte


ALY


71109


Antibodies to tissue antigens — mitochondria


MA


71119


Antibodies to tissue antigens — neuron


ANE


71109


Antibodies to tissue antigens — neutrophil cytoplasm


ANCA


71153


Antibodies to tissue antigens — ovary


AOV


71109


Antibodies to tissue antigens — parathyroid


PTHA


71109


Antibodies to tissue antigens — platelet


APA


71109


Antibodies to tissue antigens — PM-Sc1


PM1


71119


Antibodies to tissue antigens — reticulin


RCA


71119


Antibodies to tissue antigens — salivary gland


ASG


71109


Antibodies to tissue antigens — Scl-70


SCL


71119


Antibodies to tissue antigens — skeletal muscle


SLA


71109


Antibodies to tissue antigens — skin basement membrane


SKA


71109


Antibodies to tissue antigens — smooth muscle


SMA


71119


Antibodies to tissue antigens — thyroglobulin


ATG


71109


Antibodies to tissue antigens — thyroid microsome


TMA


71109


Antibodies to tissue antigens — tissue transglutaminase


TTG


71163


Antibodies to tissue antigens — TSH receptor antibody test


TSHA


71109


Antibody testing, microbial (see Microbial)




Antigen testing, microbial (see Microbial)




Antithrombin III


ATH


65132-36, 65142, 65171


Anti-Xa activity


QAXA


65147


Anus — cytology on specimens from


SMCY


73043


Apolipoprotein B/A1 ratio


APO


66536


Arginine infusion


ARIN


66689


Arsenic


AS


66672-73


Aspartate aminotransferase


AST


66500


Aspergillus — microbial antibody testing


ASP


69384


Avian precipitins (bird fancier's disease) — microbial antibody testing


APP


69384


B12 vitamin


B12


66599


Barbiturate


BARB


66800, 66812


Beryllium


BE


66672-73


Beta-2-microglobulin


BMIC


66629


Beta-hydroxybutyrate


BHYB


66500


Bicarbonate


HCO3


66500


Bilirubin (all fractions)


BILI


66500


Bilirubin (all fractions) — in urine


UBIL


66500


Bilirubin (all fractions) — neonatal


BILN


66749


Bird fancier's disease (see avian precipitins)


APP


69384


Blastomyces — microbial antibody testing


BLM


69384


Blood — compatibility testing


XMAT


65099-108


Blood — culture


BC


69354-60


Blood — faecal occult


FOB


66764-70


Blood — film


BF


65066


Blood — full examination


FBE


65070


Blood — gases


GAS


66566


Blood — group and blood group antibodies


BGAB


65096


Blood — group antibodies


BGA


65111


Blood — group systems


BGS


65093


Blood — grouping — ABO and RH (D antigen)


BG


65090


Blood — viscosity


VISC


65060


Body cavities — aspirations of — microscopy and culture of material from


MCPO


69321


Body fluids — cytology


BFCY


73045


Bone — low mineral densities


CBLB


66773


Bone — metabolic bone disease


CBMB


66776


Bone marrow examination — aspirate


BMEA


65087


Bone marrow examination — trephine


BMET


65084


Bordetella pertussis — microbial antibody testing


BOR


69384


Borrelia burgdorferi — microbial antibody testing


BOB


69384


Breath hydrogen test


BHT


66674


Bromide


BRMD


66812


Brucella — microbial antibody testing


BRU


69384


C-l esterase inhibitor — functional


CEIF


66647


C-l esterase inhibitor — quantitation


CEIQ


66644


CA-15.3 antigen


CA15


66650


CA-19.9 antigen


CA19


66650


CA-125 antigen


C125


66650


Cadmium


CD


66672-73


Caeruloplasmin


CPLS


66632


Calcitonin


CALT


66695


Calcium — ionised


ICA


66584


Calcium (total or corrected for albumin)


CA


66500


Calculus analysis


CALC


66590


Campylobacter jejuni — microbial antibody testing


CAM


69384


Candida — microbial antibody testing


CAN


69384


Carbamazepine (Tegretol)


CARB


66800


Carboxyhaemoglobin


COHB


65117


Carcinoembryonic antigen


CEA


66650


Cardiac enzymes


CE


66506


Cardiolipin — tissue antigens — antibodies


ACL


71109


Catecholamines


CAT


66779


Cell mediated immunity — delayed type — hypersensitivity test


CMI


71137


Cell-mediated immunity in blood


CMIB


69471


Cervix — cytology — abnormalities


CCRA


73055


Cervix — cytology — routine


CCR


73053


Cervix — microscopy and culture of material from


MCGR


69312


Cervix — microscopy, culture and Chlamydia of material from


MCCH


69315


Characterisation of antibodies if positive ENA


ENAP


71103


Chemicals, toxic (ingested or absorbed) — assays


DRGO


66623


Chlamydia — investigation by any method


CHLM


69369


Chlamydia — investigation by any method and N gonorrhoea by NAA methods


CHGO


69370


Chlamydia — microbial antibody testing


CHL


69384


Chlamydia — microbial antigen testing


MCCH


69315, 69369


Chloral hydrate


CHHY


66812


Chlorazepate


CHZP


66812


Chloride


CL


66500


Chloroquine


CLOQ


66812


Chlorpromazine


CHLO


66812


Cholesterol


CHOL


66500


Cholesterol — HDL


HDLC


66536


Cholinesterase


CHSE


66758


Chorionic gonadotrophin — quantitation


HCG


66650-53, 66750, 66751, 73529


Chorionic gonadotrophin — detection for pregnancy diagnosis


HCGP


73527-29


Chromium


CR


66672-73


Chromosome identification — studies — blood


CSB


73289


Chromosome identification — studies — other than blood


CS


73287


Chromosome identification and banding



73287-89


Cimetidine


CMTD


66812


Clobazam


CLOB


66812


Clomipramine


CLOM


66812


Clonazepam (Rivotril)


CLON


66812


Clostridium difficile — microbial antigen testing


CLDT


69363


Coagulation factor inhibitors by Bethesda assay


BETH


65159


Coagulation — factors (see individual factors)




Coagulation — studies


COAG


65120


Coccidioides — microbial antibody testing


CCC


69384


Coeliac antibodies


CLC


71163-64


Cold agglutinins


CAG


65114


Collagen — low bone


CBLB


66773


Collagen — metabolic disease


CBMB


66776


Compatibility testing


XMAT


65099-108


Complement, total haemolytic


COM


71081


Complement, total haemolytic — components C3


C3


71083


Complement, total haemolytic — components C4


C4


71083


Complement, total haemolytic — other components


COMP


71089


Complement, total haemolytic — properdin factor B


PFB


71083


Copper


CU


66669-70


Cortisol


CORT


66695


Coxsackie B1-6 — microbial antibody testing


COX


69384


C-Peptide


CPEP


66695


C-reactive protein


CRP


66500


Creatine kinase


CK


66500


Creatine kinase — isoenzymes


CKI


66518


Creatine kinase — isoenzymes (electrophoresis)


CKIE


66518


Creatinine


C


66500


Cryofibrinogen — detection and quantitation


CFID


71064


Cryoglobulins — characterisation by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing


RYO


71059


Cryoglobulins — detection and quantitation


CGLD


71064


Cryptococcal antigen — microbial antigen testing


CRYN


69372


Cryptococcus — microbial antibody testing


CRY


69384


CSF — microscopy and culture of material from


MCPO


69321


CSF antigens — group B streptococcus


STB


69372


CSF antigens — Haemophilus influenzae


HI


69372


CSF antigens — Neisseria meningitidis


NMG


69372


CSF antigens — Streptococcus pneumoniae


SPN


69372


Cultural examination of faeces


FCS


69345


Cyclic AMP


CAMP


66695


Cyclosporin A


CLSA


66812


Cystine — qualitative


UCYS


66752


Cystine — quantitative


CYST


66752


Cytology — fine needle aspiration of solid tissues


FNCY


73049


Cytology — fine needle aspiration of solid tissues — aspiration or attendance by a pathologist


FNCP


73051


Cytology — from 3 sputum or urine specimens


SPCY


73047


Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings


BFCY


73045


Cytology — from cervix — abnormalities


CCRA


73055


Cytology — from cervix — routine


CCR


73053


Cytology — from skin, nipple discharge, lip, mouth, nose or anus


SMCY


73043


Cytology — from vagina


CVO


73057


Cytomegalovirus — microbial antibody testing


CMV


69384


Cytomegalovirus serology in pregnancy — microbial antibody testing


CMVP


69405-11


D vitamin


VITD


66608


D-dimer test


DD


65120


Dehydroepiandrosterone sulphate (DHEAS)


DHEA


66695


Dengue — microbial antibody testing


DEN


69384


11-Deoxycortisol


DCOR


66695


Desipramine


DESI


66812


Dexamethasone


DXST


66686


Dexamethasone — suppression test


DEXA


66686


DHEAS (Dehydroepiandrosterone sulphate)


DHEA


66695


Diazepam


DIAZ


66812


Differential cell count


DIFF


65070


Digoxin


DIG


66800


Dihydrotestosterone


DHTS


66695


Diphenylhydantoin (Dilantin)


DIL


66812


Diphtheria — microbial antibody testing


DIP


69384


Direct Coombs test


CMBS


65114


Disopyramide (Rythmodan)


DISO


66800


DNA binding — quantitation and measurement if positive ANA


ANAP


71099


DNA (double-stranded DNA) antibody


DSDNA


71099


Donath Landsteiner antibody test


DLAT


65075


Down's syndrome and neural tube defects


NTDD


66750, 66751


Doxepin hydrochloride


DOXE


66812


Drugs — abuse treatment programme — assay


DATP


66626


Drugs — inappropriate dosage — assay


DRGO


66623


Drugs — therapeutic — assay (see individual drugs)



66800, 66812


Dynamic function tests


GHSE


66686


Ear — microscopy and culture of material from


MCSW


69303


Echinococcus — microbial antibody testing


ECC


69384


Echis test


ECHI


65120


ECHO-coxsackie group — microbial antibody testing


ECH


69384


Electrolytes


E


66509


Electron microscopy of biopsy material


EM


72851-52


Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of cryoglobulins


RYO


71059


Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of paraprotein


PRYO


71059


Electrophoresis, to demonstrate — creatine kinase isoenzymes


CKIE


66518


Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes


LDI


66641


Electrophoresis, to demonstrate — lipoprotein subclasses


LEPG


66539


Electrophoresis, to demonstrate — quantitation of protein classes, or paraprotein


EPPI


71057-58


Elements (see individual elements)




Endomysium antibodies


EMA


71163


Entamoeba histolytica — microbial antibody testing


AMO


69384


Enzyme assays of solid tissue or tissues


ENZS


66683


Enzyme histochemistry of skeletal muscle


EHSK


72844


Eosinophil cationic protein


ECP


71095


Epstein Barr virus — microbial antibody testing


EBV


69472-74


Erythrocyte — assessment of haemolysis


ERYH


65075


Erythrocyte — assessment of metabolic enzymes


ERYM


65075


Erythrocyte — count


RCC


65070


Erythrocyte — sedimentation rate


ESR


65060


Ethanol (alcohol)


ETOH


66626, 66800


Ethosuximide (Zarontin)


ETHO


66800


Extractable nuclear antigens — detection of antibodies to


ENA


71101


Eye — microscopy and culture of material from


MCSW


69303


Factor II


FII


65150


Factor V


FV


65150


Factor V Leiden mutation


FVLM


65168, 65174


Factor VII


FVII


65150


Factor VIII


VIII


65150


Factor IX


FIX


65150


Factor X


FX


65150


Factor XI


FXI


65150


Factor XII


FXII


65150


Factor XIII


XIII


65150


Factor XIII deficiency test


F13D


65120


Faecal antigen test for Helicobacter pylori


FAHP


69372


Faecal blood


FOB


66764-70


Faecal fat


FFAT


66674


Faecal fat — haemoglobin


FFH


66764


Faecal fat — reducing substances


FRS


66761


Faeces — culture


FCS


69345


Faeces — microscopy for parasites


OCP


69336-39


Ferritin (see also Iron studies)


FERR


66593


Fibrin monomer


FM


65120


Fibrinogen


FIB


65120


Fibrinogen — degradation products


FDP


65120


Fitzgerald factor


FGF


65150


Flecainide


FLEC


66812


Fletcher factor


FF


65150


Fluorescent treponemal antibody — absorption test (FTA-ABS) — microbial antibody testing


FTA


69384


Fluoxetine


FLUX


66812


Foetal red blood cells — Kliehauer


KLEI


65162


Folate — red cell


RCF


66599


Follicle stimulating hormone (FSH)


FSH


66695


Fragile X


FXS


73300, 73305


Frozen section diagnosis of biopsy material


FS


72855-56


Fructosamine


FRUC


66557


Full blood examination


FBE


65070


Gamma glutamyl transpeptidase


GGT


66500


Gastric parietal cell — tissue antigens — antibodies


PCA


71119


Gastrin


GAST


66695


Gentamicin



66800


Gliadin IgA — tissue antigens — antibodies


GLIA


71163


Globulin


GLOB


66500


Glomerular basement membrane — tissue antigens — antibodies


GBA


71109


Glucagon


GLGO


66695


Glucagon stimulation test


GSTC


66689


Glucose


GLUC


66500


Glucose — tolerance test


GTT


66542


Glycosylated haemoglobin (Hb Alc)


GHB


66551


Gold


AU


66672-73


Gonadotrophin


GRHS


66689


Group B streptococcus — CSF antigens


STB


69372


Group B streptococcus — microbial antigen testing


STB


69372


Group P9 — simple basic pathology tests



73801-11


Growth hormone


GH


66695


Growth hormone — stimulation by exercise or L-dopa


GHSE


66686


Growth hormone — suppression by dexamethasone or glucose


GHSG


66686


Haematocrit


HCT


65070


Haemochromatosis


FEUP


66794


Haemoglobin


HB


65060


Haemoglobinopathy tests


HMGP


65081


Haemophilus influenzae — CSF antigens


HI


69372


Haemophilus influenzae — microbial antibody testing


HUS


69384


Haemophilus influenzae — microbial antigen testing


HI


69372


Haloperidol


HALO


66812


Haptoglobins


HGLB


66632


HDL cholesterol


HDLC


66536


Heart — tissue antigens — antibodies


AHE


71109


Heparin — test


HEPR


65144


Hepatitis B or C confirmatory test


HSVP


69484


Hepatitis C — detection


RNAC


69444


Hepatitis C — genotype


GHCV


69443


Hepatitis C — quantitation


THCV


69442


Hepatitis investigation — 3 markers


HEP3


69481


Hepatitis serology — in pregnancy


HEPP


69405-13


Hepatitis status or carriage — 1 marker


HEP1


69475


Hepatitis status or carriage — 2 markers


HEP2


69478


Hepatitis status or carriage — 3 markers


HEP3


69481


Herpes simplex virus — direct detection from clinical material


HSV


69375


Herpes simplex virus — investigation by culture


HSVC


69375


Herpes simplex virus — microbial antibody testing


HPA


69384


Herpes simplex virus — microbial antigen testing


HSV


69375


Heterophil antibodies


IM


65114


HIAA (hydroxyindoleacetic acid)


HIAA


66779


Histamine


HIAM


66779


Histone — tissue antigens — antibodies


AHI


71109


Histopathology of biopsy material


HIST


72813-36


Histoplasma — microbial antibody testing


HIP


69384


HIV — antiretroviral therapy


TVLT


69381


HIV — cerebrospinal fluid


CVLT


69382


HIV — monitoring


MVLT


69378


HLA typing — HLA class 1


HLA1


71149


HLA typing — HLA class 2


HLA2


71151


HLA typing — HLA-B27


HLAB


71147


HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA)


HMMA


66779


HMPG (hydroxy-methoxy phenylethylene glycol)


HMPG


66779


Homovanillic acid


HVA


66779


Hormone receptor assay — breast


HRA


66662


Hormone receptor assay — ovary


HRO


66662


Hormones — stimulation by exercise or L-dopa


GHSE


66686


Hormones — 11 deoxycortisol


DCOR


66695


Hormones — adrenocorticotrophic hormone


ACTH


66695


Hormones — aldosterone


ALDS


66695


Hormones — androstenedione


ANDR


66695


Hormones — calcitonin


CALT


66695


Hormones — cortisol


CORT


66695


Hormones — C-Peptide


CPEP


66695


Hormones — cyclic AMP


CAMP


66695


Hormones — dehydroepiandrosterone sulphate (DHEAS)


DHEA


66695


Hormones — dihydrotestosterone


DHTS


66695


Hormones — follicle stimulating hormone


FSH


66695


Hormones — gastrin


GAST


66695


Hormones — glucagon


GLGO


66695


Hormones — gonadotrophin


GRHS


66689


Hormones — growth hormone


GH


66695


Hormones — growth hormone — stimulation by exercise or L-dopa


GHSE


66686


Hormones — growth hormone — suppression by dexamethasone or glucose


GHSG


66686


Hormones — hormone receptor assay — breast


HRA


66662


Hormones — hormone receptor assay — ovary


HRO


66662


Hormones — human chorionic gonadotrophin — detection for pregnancy diagnosis


HCGP


73527, 73529


Hormones — human chorionic gonadotrophin — quantitation


HCG


66650-53, 66750, 66751, 73529


Hormones — hydroxyprogesterone


OHP


66695


Hormones — insulin


INS


66695


Hormones — insulin, hypoglycaemia test


INHY


66689


Hormones — luteinizing hormone


LH


66695


Hormones — oestradiol


E2


66695


Hormones — oestriol


E3


66750, 66751


Hormones — oestrone


E1


66695


Hormones — parathyroid hormone


PTH


66695


Hormones — pentagastrin


PSTR


66689


Hormones — progesterone


PROG


66695


Hormones — prolactin


PROL


66695


Hormones — renin


REN


66695


Hormones — sex hormone binding globulin


SHBG


66695


Hormones — somatomedin


SOMA


66695


Hormones — suppression by dexamethasone or glucose


GHSG


66686


Hormones — testosterone


TES


66695


Hormones — urine steroid fraction or fractions


USF


66695


Hormones — vasoactive intestinal peptide


VIP


66695


Hormones — vasopressin


ADH


66695


Hormones and hormone binding proteins (see individual hormones and proteins)



66695


Huhner's test


HT


73521


Human chorionic gonadotrophin — detection for pregnancy diagnosis


HCGP


73527, 73529


Human chorionic gonadotrophin — quantitation


HCG


66650-53, 66750, 66751, 73529


HVA (homovanillic acid)


HVA


66779


Hydatid — microbial antibody testing


HYD


69384


Hydroxy methoxy phenylethylene glycol


HMPG


66779


Hydroxy-3-methoxymandelic acid (previously known as VMA)


HMMA


66779


Hydroxychloroquine


HOCQ


66812


Hydroxyindoleacetic acid


HIAA


66779


Hydroxyprogesterone


OHP


66695


Hydroxyproline


HYDP


66752


Imipramine


IMIP


66812


Immediate frozen section diagnosis of biopsy material


FS


72855-56


Immunocyto. 1-3 antibodies


ICC


73059, 73061


Immunocyto. 4+ antibodies


ICC1


73060


Immunoelectrophoresis and electrophoresis —characterisation of cryoglobulins


RYO


71059


Immunoelectrophoresis and electrophoresis —characterisation of paraprotein


PPRO


71059


Immunoglobulins — A


IGA


71066


Immunoglobulins — D


IGD


71074


Immunoglobulins — E (total)


IGE


71075-79


Immunoglobulins — G


IGG


71068


Immunoglobulins — G, 4 subclasses


SIGG


71073


Immunoglobulins — M


IGM


71072


Immunohistochemical investigation of biopsy material


HIS


72846-48


Infectious mononucleosis


IM


69384


Influenza A — microbial antibody testing


FLA


69384


Influenza B — microbial antibody testing


FLB


69384


Insulin


INS


66695


Insulin — hypoglycaemia test


INHY


66689


Insulin — tissue antigens — antibodies


AINS


71109


Insulin receptor antibodies — tissue antigens — antibodies


INSA


71109


Intercellular cement substance of skin — tissue antigens — antibodies


ICCS


71109


Intestinal disaccharidases


INTD


66680


Intrinsic factor — tissue antigens — antibodies


AIF


71109


Iron studies (iron, transferrin and ferritin)


IS


66596


Islet cell — tissue antigens — antibodies


AIC


71109


Isoelectric focussing and electrophoresis —characterisation of cryoglobulins


RYO


71059


Isoelectric focussing and electrophoresis —characterisation of paraprotein


PPRO


71059


Jo-1 — tissue antigens — antibodies


JO1


71119


Keratin — tissue antigens — antibodies


KERA


71119


Kleihauer test


KLEI


65162


Lactate


LACT


66500


Lactate — dehydrogenase


LDH


66500


Lactate — dehydrogenase isoenzymes


LDI


66641


Lamellar body phospholipid


LBPH


66749


Lead


PB


66665


Lecithin/sphingomyelin ratio (amniotic fluid)


LS


66749


Legionella pneumophila — serogroup 1 — microbial antibody testing


LP1


69384


Legionella pneumophila — serogroup 2 — microbial antibody testing


LP2


69384


Leishmaniasis — microbial antibody testing


LEI


69384


Leptospira — microbial antibody testing


LEP


69384


Leucocyte count


WCC


65070


Leucocyte count — 3 surface markers — blood, CSF, serous fluid


LMH3


71139


Leucocyte count — 3 surface markers — tissue


LMT3


71141


Leucocyte count — 6 surface markers — blood, CSF, serous fluid and tissue(s)


LMHT


71145


Leucocyte count — 6 surface markers — blood, CSF, serous fluid or tissue


LM6


71143


Leucocyte count — CD34 surface marker only — blood


LMCD34


71146


Lignocaine


LIGN


66800


Lip — cytology on specimens from


SMCY


73043


Lipase


LIP


66500


Lipid studies


FATS


66500


Lipoprotein subclasses — electrophoresis


LEPG


66539


Listeria — microbial antibody testing


LIS


69384


Lithium


LI


66800


Liver function tests


LFT


66515


Liver/kidney microsomes — tissue antigens — antibodies


LKA


71119


Lupus anticoagulant


LUPA


65132-37, 65142


Luteinizing hormone


LH


66695


Lymphocyte — tissue antigens — antibodies


ALY


71109


Lymphocytes — functional tests — 1 test


LF1


71127


Lymphocytes — functional tests — 2 tests


LF2


71129


Lymphocytes — functional tests — 3 tests


LF3


71131


Magnesium


MG


66500


Mammary serum antigen


MSA


66650


Manganese


MN


66669-70


Mantoux test


MANT


73811


Measles — microbial antibody testing


MEA


69384


Mercury


HG


66672-73


Metabolic bone disease


CBMB


66776


Metanephrines


MNEP


66779


Methadone


MTDN


66812


Methaemalbumin detection (Schumm's test)


SCHM


65117


Methotrexate


MTTA


66812


Methsuximide


MSUX


66812


Methylphenobarbitone


MPBT


66812


Metronidazole


MRDZ


66812


Mexiletine (Mexitil)


MEX


66812


Mianserin


MIAS


66812


Microalbumin


MALB


66560


Microbial antibody testing — actinomycetes


ACT


69384


Microbial antibody testing — adenovirus


ADE


69384


Microbial antibody testing — aspergillus


ASP


69384


Microbial antibody testing — avian precipitins (bird fancier's disease)


APP


69384


Microbial antibody testing — Blastomyces


BLM


69384


Microbial antibody testing — Bordetella pertussis


BOR


69384


Microbial antibody testing — Borrelia burgdorferi


BOB


69384


Microbial antibody testing — Brucella


BRU


69384


Microbial antibody testing — Campylobacter jejuni


CAM


69384


Microbial antibody testing — Candida


CAN


69384


Microbial antibody testing — Chlamydia


CHL


69384


Microbial antibody testing — Coccidioides


CCC


69384


Microbial antibody testing — Coxsackie B1-6


COX


69384


Microbial antibody testing — cryptococcus


CRY


69384


Microbial antibody testing — cytomegalovirus


CMV


69384


Microbial antibody testing — cytomegalovirus serology in pregnancy


CMVP


69384


Microbial antibody testing — dengue


DEN


69384


Microbial antibody testing — diphtheria


DIP


69384


Microbial antibody testing — echinococcus


ECC


69384


Microbial antibody testing — echo-coxsackie group


ECH


69384


Microbial antibody testing — Entamoeba histolytica


AMO


69384


Microbial antibody testing — Epstein Barr virus


EBV


69472-74


Microbial antibody testing — fluorescent treponemal antibody — absorption test
(FTA-ABS)


FTA


69384


Microbial antibody testing — Haemophilus influenzae


HUS


69384


Microbial antibody testing — herpes simplex virus


HPA


69384


Microbial antibody testing — Histoplasma


HIP


69384


Microbial antibody testing — hydatid


HYD


69384


Microbial antibody testing — infectious mononucleosis


IM


69384


Microbial antibody testing — influenza A


FLA


69384


Microbial antibody testing — influenza B


FLB


69384


Microbial antibody testing — Legionella pneumophila — serogroup 1


LP1


69384


Microbial antibody testing — Legionella pneumophila — serogroup 2


LP2


69384


Microbial antibody testing — leishmaniasis


LEI


69384


Microbial antibody testing — Leptospira


LEP


69384


Microbial antibody testing — Listeria


LIS


69384


Microbial antibody testing — measles


MEA


69384


Microbial antibody testing — Micropolyspora faeni


MIC


69384


Microbial antibody testing — mumps


MUM


69384


Microbial antibody testing — Murray Valley encephalitis


MVE


69384


Microbial antibody testing — Mycoplasma pneumoniae


MYC


69384


Microbial antibody testing — Neisseria meningitidis


MEN


69384


Microbial antibody testing — Newcastle disease


NCD


69384


Microbial antibody testing — parainfluenza 1


PF1


69384


Microbial antibody testing — parainfluenza 2


PF2


69384


Microbial antibody testing — parainfluenza 3


PF3


69384


Microbial antibody testing — paratyphi


PTY


69384


Microbial antibody testing — pertussis


PER


69384


Microbial antibody testing — poliomyelitis


PLO


69384


Microbial antibody testing — Proteus OX 19


POX


69384


Microbial antibody testing — Proteus OXK


POK


69384


Microbial antibody testing — Q fever


QFF


69384


Microbial antibody testing — rapid plasma reagin test


RPR


69384


Microbial antibody testing — respiratory syncytial virus


RSV


69384


Microbial antibody testing — Ross River virus


RRV


69384


Microbial antibody testing — rubella


RUB


69384


Microbial antibody testing — Salmonella typhi (H)


SAH


69384


Microbial antibody testing — Salmonella typhi (O)


SAO


69384


Microbial antibody testing — Schistosoma


STO


69384


Microbial antibody testing — streptococcal serology — anti-DNASE B titre


ADNB


69384


Microbial antibody testing — streptococcal serology — anti-streptolysin O titre


ASOT


69384


Microbial antibody testing — Streptococcus pneumoniae


PCC


69384


Microbial antibody testing — tetanus


TET


69384


Microbial antibody testing — Thermoactinomyces vulgaris


THE


69384


Microbial antibody testing — thermopolyspora


TPS


69384


Microbial antibody testing — Toxocara


TOC


69384


Microbial antibody testing — toxoplasma


TOX


69384


Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)


TPHA


69384


Microbial antibody testing — Treponema pallidum haemagglutination test


TPHA


69384


Microbial antibody testing — trichinosis


TOS


69384


Microbial antibody testing — typhus, Weil-Felix


TYP


69384


Microbial antibody testing — Varicella zoster


VCZ


69384


Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)


VDRL


69384


Microbial antibody testing — Yersinia enterocolitica


YER


69384


Microbial antigen testing — Chlamydia


MCCH


69315, 69369


Microbial antigen testing — Clostridium difficile


CLDT


69363


Microbial antigen testing — group B streptococcus


STB


69372


Microbial antigen testing — Haemophilus influenzae


HI


69372


Microbial antigen testing — herpes simplex virus


HSV


69375


Microbial antigen testing — Neisseria gonorrhoeae


GON


69372


Microbial antigen testing — Neisseria meningitidis


NMG


69372


Microbial antigen testing — respiratory syncytial virus


RSVN


69372


Microbial antigen testing — Streptococcus pneumoniae


SPN


69372


Microbial antigen testing — Varicella zoster


VCZN


69375


Micropolyspora faeni


MIC


69384


Microscopic examination of — faeces for parasites


OCP


69336-39


Microscopic examination of — wet film material other than blood


MWFM


69300


Microscopy and culture of — material from nose, throat, eye or ear


MCSW


69303


Microscopy and culture of — material from skin


MCSK


69309


Microscopy and culture of — postoperative wounds, aspirates of body cavities


MCPO


69321


Microscopy and culture of — superficial sites


MCSS


69306


Microscopy and culture of — urethra, vagina, cervix or rectum


MCGR


69312


Microscopy and culture of — specimens of sputum


MCSP


69318


Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 1 specimen


AFB1


69324


Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 2 specimens


AFB2


69327


Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 3 specimens


AFB3


69330


Microscopy and culture to detect pathogenic micro-organisms including chlamydia


MCCH


69315


Microscopy, culture, identification and sensitivity of urine


UMCS


69333


Mitochondria — tissue antigens — antibodies


MA


71119


Mouth — cytology on specimens from


SMCY


73043


Mumps — microbial antibody testing


MUM


69384


Murray Valley encephalitis — microbial antibody testing


MVE


69384


Mycobacteria microscopy and culture of sputum — 1 specimen


AFB 1


69324


Mycobacteria microscopy and culture of sputum — 2 specimens


AFB 2


69327


Mycobacteria microscopy and culture of sputum — 3 specimens


AFB 3


69333


Mycoplasma pneumoniae — microbial antibody testing


MYC


69384


Myoglobin


MYOG


66518


N-acetyl procainamide


NAPC


66812


Neisseria gonorrhoeae by NAA techniques and chlamydia by any method


CHGO


69370


Neisseria gonorrhoeae — microbial antigen testing


GON


69372


Neisseria meningitidis — antigens


NMG


69372


Neisseria meningitidis — microbial antibody testing


MEN


69384


Neisseria meningitidis — microbial antigen testing


NMG


69372


Netilmicin



66800


Neural tube defects and Down's syndrome


NTDD


66750, 66751


Neuron — tissue antigens — antibodies


ANE


71109


Neutrophil cytoplasm — tissue antigens — antibodies


ANCA


71109


Neutrophil functions


NFT


71135


Newcastle disease — microbial antibody testing


NCD


69384


Nickel


NI


66672-73


Nipple discharge — cytology on specimens from


SMCY


73043


Nitrazepam


NITR


66812


Nordothiepin


NDIP


66812


Norfluoxetine


NFLE


66812


Nortriptyline


NORT


66812


Nose — cytology on specimens from


SMCY


73043


Nose — microscopy and culture of material from


MCSW


69303


Nuclear antigens — detection of antibodies to


ANA


71097


Oestradiol


E2


66695


Oestriol


E3


66750, 66751


Oestrone


E1


66695


Oligoclonal proteins


OGP


71062


Op/biopsy specimens — microscopy and culture of material from


MCPO


69321


Oral glucose challenge test — gestational diabetes


OGCT


66545


Oral glucose tolerance test — gestational diabetes


GTTP


66542


Osmolality, serum or urine


OSML


66563


Ovary — tissue antigens — antibodies


AOV


71109


Oxalate


OXAL


66752


Oxazepam


OXAZ


66812


PAA (phenyl acetic acid)


PAA


66779


Palmitic acid in amniotic fluid


PALM


66749


Pap smear


CCR


73053


Papanicolaou test


CCR


73053


Paracetamol


PARA


66800


Parainfluenza 1 — microbial antibody testing


PF1


69384


Parainfluenza 2 — microbial antibody testing


PF2


69384


Parainfluenza 3 — microbial antibody testing


PF3


69384


Paraprotein characterisation — by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing


PPRO


71059


Paraprotein characterisation — on concurrently collected serum or urine


PPSU


71060


Paraprotein quantitation — by electrophoresis


EPPI


71057


Paraquat


PARQ


66812


Parasites — microscopic examination of faeces


OCP


69336-39


Parathyroid hormone (PTH)


PTH


66695


Parathyroid — tissue antigens — antibodies


PTHA


71109


Paratyphi — microbial antibody testing


PTY


69384


Partial thromboplastin time


PTT


65120


Patient episode initiation fees


PEI


73901-15


Pentagastrin


PSTR


66689


Pentobarbitone


PENT


66812


Perhexiline


PHEX


66812


Pertussis — microbial antibody testing


PER


69384


Phenobarbitone


PHBA


66800


Phensuximide


PHEN


66812


Phenylacetic acid


PAA


66779


Phenytoin


PHEY


66800


Phosphate


PHOS


66500


Phosphatidylglycerol


PTGL


66749


Plasminogen


PLAS


65139


Platelet — aggregation


PLTG


65144


Platelet — count


PLTC


65070


Platelet — tissue antigens — antibodies


APA


71109


PM-Sc1 — tissue antigens — antibodies


PM1


71119


Poliomyelitis — microbial antibody testing


PLO


69384


Porphobilinogen in urine


UPG


66782


Porphyrins — quantitative test, 1 or more fractions


PR


66785


Porphyrins in urine — qualitative test


UPR


66782


Potassium


K


66500


Prealbumin


PALB


66632


Prednisolone


PRED


66812


Pregnancy serology — 1 test


MSP1


69405


Pregnancy serology — 2 tests


MSP2


69408


Pregnancy serology — 3 tests


MSP3


69411


Pregnancy serology — 4 tests


MSP4


69413


Pregnancy testing



73806


Pregnancy testing — diagnosis of Down's syndrome and neural tube defect


NTDD


66750, 66751


Pregnancy testing — HCG detection


HCG


73527, 73529


Pregnancy testing — HCG quantitation


HCG


73529


Primidone


PRIM


66800


Procainamide


PCAM


66800


Progesterone


PROG


66695


Prolactin


PROL


66695


Propranolol


PPNO


66812


Prostate specific antigen


PSA


66655-59


Protein — C


PROC


65132-36, 65142, 65171


Protein — S


PROS


65132-36, 65142, 65171


Protein, quantitation of — alpha fetoprotein


AFP


66650-53, 66743, 66750, 66751


Protein, quantitation of — alpha-l-antitrypsin


AAT


66635


Protein, quantitation of — beta-2-microglobulin


BMIC


66629


Protein, quantitation of — caeruloplasmin


CPLS


66632


Protein, quantitation of — C-l esterase inhibitor


CEI


66644


Protein, quantitation of — classes or presence and amount of paraprotein by electrophoresis


EPPI


71057, 71058


Protein, quantitation of — ferritin (see also Iron studies)


FERR


66593


Protein, quantitation of — for Down's syndrome/neural tube defect testing


NTDD


66750, 66751


Protein, quantitation of — haptoglobins


HGLB


66632


Protein, quantitation of — microalbumin


MALB


66560


Protein, total — quantitation of


PROT


66500


Proteus OX 19 — microbial antibody testing


POX


69384


Proteus OXK — microbial antibody testing


POK


69384


Prothrombin gene mutation


PGM


65168, 65174


Prothrombin time


PT


65120


Pyruvate


PVTE


66500


Q fever — microbial antibody testing


QFF


69384


Quinalbarbitone


QUIB


66812


Quinidine


QUIN


66800


Quinine


QNN


66812


Rapid plasma reagin test — microbial antibody testing


RPR


69384


RAST


RAST


71079


Rectum — microscopy and culture of material from


MCGR


69312


Rectum — microscopy, culture and Chlamydia of material from


MCCH


69315


Red blood cells — Kleihauer


KLEI


65162


Red cell folate and serum B12


B12F


66602


Red cell folate and serum B12 and serum folate if required


B12F


66602


Red cell folate and serum folate


RCF


66599


Red cell porphyrins — qualitative test


RCP


66782


Referred specimen fee



73921


Renin


REN


66695


Reptilase test


REPT


65120


Respiratory syncytial virus — microbial antibody testing


RSV


69384


Respiratory syncytial virus — microbial antigen testing


RSVN


69372


Reticulin — tissue antigens — antibodies


RCA


71119


Reticulocyte count


RETC


65072


Rheumatoid factor


RF


71106


Rheumatoid factor — quantitation


RFQ


71106


Ross River virus — microbial antibody testing


RRV


69384


RSV (respiratory syncytial virus) — microbial antibody testing


RSV


69384


RSV (respiratory syncytial virus) — microbial antigen testing


RSVN


69372


Rubella — serology


RUB


69384


Salicylate (aspirin)


SALI


66800


Salivary gland — tissue antigens — antibodies


ASG


71109


Salmonella typhi (H) — microbial antibody testing


SAH


69384


Salmonella typhi (O) — microbial antibody testing


SAO


69384


Schistosoma — microbial antibody testing


STO


69384


Scl-70 — tissue antigens — antibodies


SCL


71119


Secretin


SSGR


66689


Selenium


SE


66669-70


Semen examination


SEE


73523


Semen examination — for spermatozoa (post vasectomy)


SES


73521


Serology — in pregnancy (see Pregnancy serology)




Serotonin


5HT


66779


Serum — Bl2


B12


66599


Serum — folate (with Bl2 red cell folate)


B12F


66602


Serum — folate (with Bl2)


B12


66599


Sex hormone binding globulin


SHBG


66695


Skeletal muscle — tissue antigens — antibodies


SLA


71109


Skin — cytology


SMCY


73043


Skin — microscopy and culture of material from


MCSS


69306


Skin — microscopy, culture and Chlamydia of material from


MCSK


69309


Skin basement membrane — tissue antigens — antibodies


SKA


71109


Smooth muscle — tissue antigens — antibodies


SMA


71119


Snake venom


HISS


66623


Sodium


NA


66500


Solid tissue or tissues — chemical assays


ENZS


66683


Solid tissue or tissues — cytology of fine needle aspiration


FNCY


73049


Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of pathologist


FNCP


73051


Somatomedin


SOMA


66695


Sotalol


SALL


66812


Specific IgE or IgG antibodies


RAST


71079


Specimen referred fee



73921


Sperm antibodies


SAB


73525


Sperm antibodies — penetrating ability


SPA


73525


Sputum — cytology (1 specimen)


BFCY


73045


Sputum — cytology (3 specimens)


SPCY


73047


Sputum — for mycobacteria — 1 specimen


AFB1


69324


Sputum — for mycobacteria — 2 specimens


AFB2


69327


Sputum — for mycobacteria — 3 specimens


AFB3


69330


Sputum — microscopy and culture of specimens


MCSP


69318


Stelazine


STEL


66812


Steroid fraction or fractions in urine


USF


66695


Streptococcal serology — anti-DNASE B titre — microbial antibody testing


ADNB


69384


Streptococcal serology — anti-streptolysin O titre — microbial antibody testing


ASOT


69384


Streptococcus — Group B


STB


69372


Streptococcus pneumoniae — CSF antigens


SPN


69372


Streptococcus pneumoniae — microbial antibody testing


PCC


69384


Streptococcus pneumoniae — microbial antigen testing


SPN


69372


Strontium


SR


66672-73


Stypven test


STYP


65120


Sugar water test


SWT


65075


Sulthiame (Ospolot)


SUL


66812


Supplementary testing for Hepatitis C antibodies


HCST


69441


Synacthen stimulation test


SYNS


66689


Syphilis serology


STS


69387


Testosterone


TES


66695


Tetanus — microbial antibody testing


TET


69384


Thalassaemia studies


TS


65078


Theophylline


THEO


66800


Thermoactinomyces vulgaris — microbial antibody testing


THE


69384


Thermopolyspora — microbial antibody testing


TPS


69384


Thiopentone


TOPO


66812


Thioridazine


THIO


66812


Throat — microscopy and culture of material from


MCSW


69303


Thrombin time


TT


65120


Thrombophilia testing (see individual thrombophilia tests)




Thyroglobulin


TGL


66650


Thyroglobulin — tissue antigens — antibodies


ATG


71109


Thyroid function tests (including TSH)


TFT


66719


Thyroid microsome — tissue antigens — antibodies


TMA


71109


Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)


TSH


66716


Thyroid stimulating hormone (if requested with other hormones referred to in item 66695)


TSH


66722-34


Thyrotrophin releasing hormone test


TRH


66689


Tissue transglutaminase antibodies


TTG


71163


Tobramycin



66800


Total protein


PROT


66500


Toxocara — microbial antibody testing


TOC


69384


Toxoplasma — microbial antibody testing


TOX


69384


TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing


TPHA


69384


Treponema pallidum haemagglutination test — microbial antibody testing


TPHA


69384


Trichinosis — microbial antibody testing


TOS


69384


Triglycerides


TRIG


66500


Trimipramine


TRIM


66812


Troponin


TROP


66518


Tryptic activity in faeces


TAF


66677


TSH receptor antibody test — tissue antigens — antibodies


TSHA


71109


Tuberculosis


MANT


73811


Tumour markers — CA-15.3 antigen


CA15


66650


Tumour markers — CA-19.9 antigen


CA19


66650


Tumour markers — CA-125 antigen


C125


66650


Tumour markers — carcinoembryonic antigen


CEA


66650


Tumour markers — mammary serum antigen


MSA


66650


Tumour markers — prostate specific antigen


PSA


66656


Tumour markers — prostatic acid phosphatase — 1 or more fractions


ACP


66656


Tumour markers — thyroglobulin


TGL


66650


Typhus, Weil-Felix — microbial antibody testing


TYP


69384


Urate


URAT


66500


Urea 


U


66500


Urea, electrolytes, creatinine


U&E


66515


Urethra — microscopy and culture of material from


MCGR


69312


Urethra — microscopy, culture and Chlamydia of material from


MCCH


69315


Urine — acidification test


UAT


66587


Urine — catalase test


UCAT


73805


Urine — cystine (cysteine)


UCYS


66782


Urine — cytology — on 1 specimen


BFCY


73045


Urine — cytology — on 3 specimens


SPCY


73047


Urine — haemoglobin


UHB


66782


Urine — microscopy, culture, identification and sensitivity


UMCS


69333


Urine — porphobilinogen


UPG


66782


Urine — porphyrins — qualitative test


UPR


66782


Urine — steroid fraction or fractions


USF


66695


Urine — urobilinogen


UUB


66782


Vagina — microscopy and culture of material from


MCGR


69312


Vagina — microscopy, culture and Chlamydia of material from


MCCH


69315


Vagina — cytology on specimens from


CVO


73057


Valproate (Epilim)


VALP


66800


Vancomycin


VAN


66800


Varicella zoster — microbial antibody testing


VCZ


69384


Varicella zoster — microbial antigen testing


VCZN


69372


Vasoactive intestinal peptide


VIP


66695


Vasopressin


ADH


66695


VDRL (Venereal Disease Research Laboratory) — microbial antibody testing


VDRL


69384


Viscosity of blood or plasma


VISC


65060


Vitamins — B12


B12


66599


Vitamins — D


VITD


66608


Vitamins — folate


RCF


66599


Vitamins — quantitation of A, B1, B2, B3, B6, C or E


VIT


66605


VMA (see HMMA)




Von Willebrand's factor


VWF


65150


Von Willebrand's factor antigen


VWA


65150


Warfarin


WFR


66812


Yersinia enterocolitica — microbial antibody testing


YER


69384


Zinc


ZN


66667-70


Part 5 Complexity levels for histopathology items

Specimen type


Complexity level


Adrenal resection, neoplasm


5


Adrenal resection, not neoplasm


4


Anus, all specimens not otherwise specified


3


Anus, neoplasm, biopsy


4


Anus, neoplasm, radical resection


6


Appendix


3


Artery, all specimens not otherwise specified


3


Artery, biopsy


4


Bartholin's gland — cyst


3


Bile duct, resection — all specimens


6


Bone, biopsy, curettings or fragments — lesion


5


Bone, biopsy or curettings quantitation — metabolic disease


6


Bone, femoral head


4


Bone, resection, neoplasm — all sites and types


6


Bone marrow, biopsy


4


Bone — all specimens not otherwise specified


4


Brain neoplasm, resection — cerebello-pontine angle


4


Brain or meninges, biopsy — all lesions


5


Brain or meninges, not neoplasm — temporal lobe


6


Brain or meninges, resection — neoplasm (intracranial)


5


Brain or meninges, resection — not neoplasm


4


Branchial cleft, cyst


4


Breast, excision biopsy, guidewire localisation — non-palpable lesion


6


Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease — all specimen types


6


Breast, incision biopsy or needle biopsy, malignant neoplasm — all specimen types


4


Breast, microdochectomy


6


Breast tissue — all specimens not otherwise specified


4


Bronchus, biopsy


4


Carotid body — neoplasm


5


Cholesteatoma


3


Digits, amputation — not traumatic


4


Digits, amputation — traumatic


2


Ear, middle and inner — not cholesteatoma


4


Endocrine neoplasm — not otherwise specified


5


Extremity, amputation or disarticulation — neoplasm


6


Extremity, amputation — not otherwise specified


4


Eye, conjunctiva — biopsy or pterygium


3


Eye, cornea


4


Eye, enucleation or exenteration — all lesions


6


Eye — not otherwise specified


4


Fallopian tube, biopsy


4


Fallopian tube, ectopic pregnancy


4


Fallopian tube, sterilization


2


Fetus with dissection


6


Foreskin — new born


2


Foreskin — not new born


3


Gallbladder


3


Gallbladder and porta hepatis-radical resection


6


Ganglion cyst, all sites


3


Gum or oral mucosa, biopsy


4


Heart valve


4


Heart — not otherwise specified


5


Hernia sac


2


Hydrocele sac


2


Jaw, upper or lower, including bone — radical resection for neoplasm


6


Joint and periarticular tissue, without bone — all specimens


3


Joint tissue, including bone — all specimens


4


Kidney, biopsy including transplant


5


Kidney, nephrectomy transplant


5


Kidney, partial or total nephrectomy or nephroureterectomy — neoplasm


6


Kidney, partial or total nephrectomy — not neoplasm


4


Large bowel (including rectum), biopsy — all sites


4


Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung's Disease


5


Large bowel, colostomy — stoma


3


Large bowel (including rectum), polyp


4


Large bowel, segmental resection — colon, not neoplasm


5


Large bowel (including rectum), segmental resection, neoplasm


6


Larynx, biopsy


4


Larynx, partial or total resection


5


Larynx, resection with nodes or pharynx or both


6


Lip biopsy — all specimens not mentioned


3


Lip wedge resection or local excision with orientation


4


Liver, hydatid cyst or resection for trauma


4


Liver, total or subtotal hepatectomy — neoplasm


6


Liver — all specimens not otherwise specified


5


Lung, needle or transbronchial biopsy


4


Lung, resection — neoplasm


6


Lung, wedge biopsy


5


Lung segment, lobar or total resection


6


Lymph node, biopsy — all sites


4


Lymph node, biopsy, for lymphoma or lymphoproliferative disorder


5


Lymph nodes, regional resection — all sites


5


Mediastinum mass


5


Muscle, biopsy


6


Nasopharynx or oropharynx, biopsy


4


Nerve, biopsy neuropathy


5


Nerve, neurectomy or removal of neoplasm


4


Nerve — not otherwise specified


3


Nose, mucosal biopsy


4


Nose or sinuses, polyps


3


Odontogenic neoplasm


5


Odontogenic or dental cyst


4


Oesophagus, biopsy


4


Oesophagus, diverticulum


3


Oesophagus, partial or total resection


6


Omentum, biopsy


4


Ovary with or without tube — neoplasm


5


Ovary with or without tube — not neoplasm


4


Pancreas, biopsy


5


Pancreas, cyst


4


Pancreas, subtotal or total with or without splenectomy


6


Parathyroid gland(s)


4


Penisectomy with node dissection


5


Penisectomy — simple


4


Peritoneum, biopsy


4


Pituitary neoplasm


4


Placenta — not third trimester


4


Placenta — third trimester, abnormal pregnancy or delivery


4


Pleura or pericardium, biopsy or tissue


4


Products of conception, spontaneous or missed abortion


4


Products of conception, termination of pregnancy


3


Prostate, radical resection


6


Prostate — all types of specimen not otherwise specified


4


Retroperitoneum, neoplasm


5


Salivary gland, Mucocele


3


Salivary gland, neoplasm — all sites


5


Salivary gland — all specimens not otherwise specified


4


Sinus, paranasal, biopsy


4


Sinus, paranasal, resection — neoplasm


6


Skin, biopsy — blistering skin diseases


4


Skin, biopsy — inflammatory dermatosis


4


Skin, biopsy — investigation of alopecia where serial horizontal sections are taken, except for male pattern baldness


5


Skin, biopsy — investigation of lymphoproliferative disorder


5


Skin, eyelid, wedge resection


4


Skin, local resection — orientation


4


Skin, resection of malignant melanoma or melanoma in situ


5


Skin — all specimens not otherwise specified including all neoplasms and cysts


3


Small bowel — biopsy, all sites


4


Small bowel, diverticulum


3


Small bowel, resection — neoplasm


6


Small bowel — all specimens not otherwise specified


5


Soft tissue, infiltrative lesion — extensive resections at least 5 cm in maximal dimension


6


Soft tissue, lipoma and variants


3


Soft tissue, neoplasm, not lipoma — all specimens


5


Soft tissue — not otherwise specified


4


Spleen


5


Stomach, endoscopic biopsy or endoscopic polypectomy


4


Stomach, resection, neoplasm — all specimens


6


Stomach — all specimens not otherwise specified


4


Tendon or tendon sheath, giant cell neoplasm


4


Tendon or tendon sheath — not otherwise specified


3


Testis, biopsy


5


Testis and adjacent structures, castration


2


Testis and adjacent structures, neoplasm with or without nodes


5


Testis and adjacent structures, vas deferens sterilization


2


Testis and adjacent structures — not otherwise specified


3


Thymus — not otherwise specified


5


Thyroglossal duct — all lesions


4


Thyroid — all specimens


5


Tissue or organ not otherwise specified, abscess


3


Tissue or organ not otherwise specified, haematoma


3


Tissue or organ not otherwise specified, malignant neoplasm with regional nodes


6


Tissue or organ not otherwise specified, neoplasm local


4


Tissue or organ not otherwise specified, pilonidal cyst or sinus


3


Tissue or organ not otherwise specified, thrombus or embolus


3


Tissue or organ not otherwise specified, veins varicosity


3


Tissue or organ — all specimens not otherwise specified


3


Tongue, biopsy


4


Tongue or tonsil, neoplasm local


5


Tongue or tonsil, neoplasm with nodes


6


Tonsil, biopsy — excluding resection of whole organ


4


Tonsil or adenoids or both


2


Trachea, biopsy


4


Ureter, biopsy


4


Ureter, resection


5


Urethra, biopsy


4


Urethra, resection


5


Urinary bladder, partial or total with or without prostatectomy


6


Urinary bladder, transurethral resection of neoplasm


5


Urinary bladder — all specimens not otherwise specified


4


Uterus, cervix, curettings or biopsy


4


Uterus, cervix cone, biopsy (including LEEP or LLETZ biopsy)


5


Uterus, endocervix, polyp


3


Uterus, endometrium, polyp


3


Uterus, with or without adnexa, malignant neoplasm — all specimen types not otherwise specified


6


Uterus with or without adnexa, neoplasm, Wertheim's or pelvic clearance


6


Uterus and/or cervix — all specimens not otherwise specified


4


Vagina, biopsy


4


Vagina, radical resection


6


Vaginal mucosa, incidental


3


Vulva or labia, biopsy


4


Vulval, subtotal or total with or without nodes


6


1. Notified in the Commonwealth of Australia Gazette on 29 October 2004.


AustLII: Copyright Policy | Disclaimers | Privacy Policy | Feedback